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Abstract 
In the last 20 years, a huge effort has been made to implement and apply the principles of 
early diagnosis and treatment, already well established in other branches of medicine, to the 
field of psychotic disorders. The goal of research on early detection was and still is to 
prospectively identify people at-risk of developing full-blown psychosis. However, until now it 
is still not possible to predict transition to psychosis with adequate accuracy. Therefore, the 
prospective Früherkennung von Psychosen (Fepsy) study aims at improving early detection 
of psychosis via a multilevel assessment containing a systematic assessment of 
psychopathological symptoms, a neuropsychological examination, blood sampling, 
electroencephalography (EEG) and magnetic resonance imaging (MRI). The present 
dissertation addresses the role of the hormone prolactin in emerging psychosis on one hand 
and on the other hand aims to elucidate whether there are any sex differences in emerging 
psychosis specifically regarding the hormone prolactin, cognitive functioning and the 
correlation of self- and observer-ratings of psychopathology. In the first publication, the role 
of the hormone prolactin in early psychosis is discussed whereas the topic of possible sex 
differences is covered by all of the publications included in this dissertation (1, 2 and 3).  
The first study validates literature by providing further evidence for frequent 
hyperprolactinemia in emerging psychosis and that it can even be observed in antipsychotic-
naïve patients (>30%). Hence, prolactin is not necessarily elevated as a side effect of 
antipsychotics but can also be a pre-existing condition probably in relation with the function 
of prolactin as stress hormone. Furthermore, all three publications which are included in this 
dissertation consider the aspect of sex differences, which may help to elucidate pathogenic 
mechanisms underlying psychosis that are specific to women or men. The first study 
demonstrated higher prolactin levels in women even after correction for the normal biological 
variation in prolactin levels between the sexes, which potentially provides an indication for a 
sex dependant stress reaction regarding the hormone prolactin. The results of our second 
study suggest that sex differences in cognitive functioning in patients are not different from 
those seen in healthy controls (HC). Specifically, the female advantage in verbal learning and 
memory, which has frequently been found in HC seems to be equally present in patients with 
an at-risk mental state (ARMS) for psychosis as well as in patients with a first episode 
psychosis (FEP). The third study shows that the associations of self- and observer-ratings of 
psychopathology were rather low and generally not different for men and women. Therefore, 
the results imply that self-rating scales cannot be a substitute for the more time-consuming 
observer-rating scales neither for men nor for women.  
In summary, prolactin plays a possible role in emerging psychosis in relation with its function 
as stress hormone and stress reactivity seems to be enhanced in women. Overall, there 
were few sex differences which could have been shown in the second and third study. 
8 
 
Regarding sex differences in cognitive functioning (publication 2), they resemble those of the 
general population and were not different between HC and patients (ARMS, FEP).  
1 General Introduction  
1.1 Early detection of psychosis 
During the past two decades, clinicians and researchers had the goal to implement and apply 
the principles of early diagnosis and treatment which are established in other branches of 
medicine, such as in oncology or in cardiovascular diseases, to the field of psychotic 
disorders. Usually, psychosis is preceded by prodromal symptoms often occurring during a 
critical life period characterized by important steps in education and building up of social 
networks. Therefore, prodromal symptoms can have serious consequences for the patient 
already in these early stages of the disease. The concepts of DUP (duration of untreated 
psychosis) and DUI (duration of untreated illness) are used to illustrate the delay of diagnosis 
and treatment. DUP, with presentation of positive psychotic symptoms, lasts on average 1 to 
3 years whereas DUI is a so-called “unspecific prodromal phase” lasting on average 2 to 5 
years also capturing subthreshold psychotic symptoms (A. Riecher-Rössler et al., 2006). A 
longer DUP has been associated with a worse overall prognosis/global outcome, lower level 
of symptomatic and functional recovery, severity of negative symptoms (Murru & Carpiniello, 
2016; Perkins, Gu, Boteva, & Lieberman, 2005), poorer social functioning (Perkins et al., 
2005), stronger impairment of psychological and social development (A. Riecher-Rössler et 
al., 2006), poorer treatment response (Perkins et al., 2005) and higher overall treatment 
costs (Ricciardi, McAllister, & Dazzan, 2008). In this context, researchers supposed to 
achieve better outcomes for the patients by intervening (early pharmacological and 
psychological treatment) already in the potential prodromal phase (Amminger et al., 2010; 
McGorry et al., 2014; Phillips et al., 2007; Woods et al., 2007). Moreover, most patients do 
also present other symptoms which require clinical attention and treatment. 
Therefore, the goal of the early detection movement is to prospectively identify people at-risk 
for developing full-blown psychosis. To capture this pre-psychotic phase, the construct of a 
clinical high-risk state (CHR) has evolved (Figure 1; Fusar-Poli et al., 2013). Basically, two 
complementary sets of criteria have been used to diagnose the CHR state, namely ultra-high 
risk (UHR) and basic symptoms (BS) criteria which are used in help-seeking individuals. 
UHR criteria describe four main sets of clinical criteria: Attenuated psychotic symptoms 
(APS), brief limited intermittent psychotic symptoms (BLIPS), genetic risk and deterioration 
syndrome (GRD) and unspecified prodromal symptoms (UPS). They were developed with 
the aim of detecting a risk for developing a first episode psychosis (Fusar-Poli et al., 2013; 
Schultze-Lutter et al., 2015).  
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The criteria adapted from BS are subjectively experienced disturbances of different domains, 
including perception, thought processing, language and attention. They were developed to 
detect the risk for psychosis even before functional impairment appeared and are mainly 
assessed with the Schizophrenia Proneness Instrument, adult version (SPI-A;  Schultze-
Lutter, Ruhrmann, Picker, & Klosterkotter, 2006).  
 
Figure 1: Model of psychosis onset from the clinical high-risk state. The higher the line on the 
y-axis, the higher the symptom severity (Fusar-Poli et al., 2013) 
 
BS: Basic symptoms; APS: Attenuated psychotic symptoms; BLIP: Brief limited intermittent psychotic episode. 
 
Several interviews have been developed to assess the UHR criteria. For a detailed 
description see Fusar-Poli et al. (2013) and Schultze-Lutter et al. (2015). Depending on the 
interview conducted, the criteria to identify UHR patients are slightly different and also the 
denomination of the so called “prodromal phase” depends on the instrument used. One of 
these interviews is the Basel Screening Instrument for Psychosis (BSIP; A. Riecher-Rössler 
et al., 2008), which has been developed in Basel in the framework of the early detection of 
psychosis project (FePsy: Früherkennung von Psychosen). In agreement with the criteria 
applied in the BSIP we will use the term “at-risk mental state” (ARMS) in this dissertation for 
all patients with a risk of developing psychosis. 
Independent of the psychometric instrument used less than 40% of patients identified as 
being in an ARMS, will actually transition to full-blown psychosis. The cumulative transition 
rates have been estimated as follows: 18% (12% - 25%) at 6 months of follow-up, 22% (17% 
- 28%) at 1 year, 29% (23% - 36%) at 2 years, 32% (24% - 35%) at 3 years, and 36% (30% - 
43%) after 3 years (Fusar-Poli et al., 2013). Hence, most of the patients identified as being in 
an ARMS will never develop a full-blown psychosis and adequate accuracy in predicting 
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conversion to psychosis is not yet possible. Therefore, early pharmacological intervention 
(antipsychotic medication already in the ARMS) is difficult to legitimate as side effects are not 
uncommon. Hence, several research projects exist around the world with the goal to improve 
prediction of psychosis. One of the first is the FePsy-study in Basel, which serves as basis 
for the present dissertation (all data presented were collected within the framework of the 
FePsy-study) and is described in the following section.  
 
1.2 Fepsy-study 
The FePsy-study is an open, prospective clinical study with a study design as depicted in 
Figure 2. All individuals are screened with the BSIP (A. Riecher-Rössler et al., 2008) which is 
largely based on the Personal Assessment and Crisis Evaluation (PACE) inclusion/exclusion 
criteria (Yung et al., 1998). The BSIP additionally allows inclusion of patients displaying a 
combination and minimal amount of certain unspecific risk factors/prodromes (different from 
other screening instruments). The patients are classified as being in an ARMS for psychosis, 
having a first episode of psychosis (FEP), or being not at risk for psychosis (usually other 
psychiatric disorders). In Table 1, BSIP criteria to fulfil an ARMS as well as BSIP criteria for 
transition to psychosis are described. 
 
Figure 2: Design of the FePsy-study (A. Riecher-Rössler et al., 2007). 
 
 
BSIP: Basel Screening Instrument for Psychosis; BPRS: Brief Psychiatric Rating Scale.  
 
All ARMS patients are followed-up at regular intervals for up to 5 years (in the first year 
monthly, second and third year 3-monthly and the last two years every year; A. Riecher-
Rössler, Pflueger, et al., 2009) in order to distinguish those who later transition to frank 
psychosis (ARMS-T) from those who do not (ARMS-NT) using the transition criteria of Yung 
et al. (1998). Exclusion criteria are as follows: age below 18 years, insufficient knowledge of 
German, IQ < 70, previous episode of schizophrenic psychosis, psychosis clearly due to 
organic reasons or substance abuse, or psychotic symptomatology within a clearly 
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diagnosed affective psychosis or borderline personality disorder. Subjects treated with 
antipsychotics for more than 3 weeks or who exceeded 2500mg cumulative chlorpromazine 
equivalent dose were excluded as well.  
 
Table 1: At-risk mental state and transition criteria in the BSIP 
Clinical signs 
At-risk mental state 
(ARMS) 
I) State (Prepsychotic)* 
- APS – “attenuated” psychotic symptoms: psychotic  symptoms 
below decompensation limit (BPRS scales: hallucinations 2-3, 
unusual thought content 3-4, suspiciousness 3-4) at least several 
times per week, in total persisting for more than 1 week or 
- BLIPS – brief limited intermittent psychotic symptoms: psychotic 
symptoms above decompensation limit (BPRS scales: hallucinations 
≥ 4, unusual thought content ≥ 5, suspiciousness ≥ 5, conceptual 
disorganisation ≥ 5), each time less than 1 week with spontaneous 
remission. 
II) Trait + State (Genetic +)* 
Genetic risk and further risk factors according to screening 
instrument (first or second degree relative with psychotic disorder 
and at least two further risk factors according to the screening 
instrument. 
III) Mixed category (Unspecific) 
Combination and minimal amount of certain unspecific risk factors 
according to screening instrument. 
 But transition criteria not yet fulfilled! 
*corresponding to PACE criteria (Yung et al., 1998) 
Transition criteria - At least one of the following symptoms: 
• Suspiciousness (BPRS ≥ 5) 
Says others are talking about him/her maliciously, have negative 
intentions or may harm him/her (incidence more than once a week 
OR partly delusional conviction) 
• Unusual thought content (BPRS ≥ 5) 
Full delusion(s) with some preoccupation OR some areas of 
functioning disrupted (not only ideas of reference/persecution, 
unusual beliefs or bizarre ideas without fixed delusional conviction) 
• Hallucinations (BPRS ≥ 4) 
Occasional hallucinations OR visual illusions > 2/week or with 
functional impairment (not only hearing of own name, non-verbal 
acoustic or formless visual hallucinations/illusions) 
• Conceptual disorganisation (BPRS ≥ 5) 
Speech difficult to understand due to circumstantiality, tangentiality, 
neologisms, blockings or topic shifts (most of the time OR 3 to 5 
instances of incoherent phrases) 
- Symptoms at least several times a week 
- Change in mental state lasting more than one week 
 
BSIP: Basler Screening Instrument for Psychosis; BPRS: Brief Psychiatric Rating Scale. 
 
All included patients (ARMS and FEP) undergo a full entry multidomain examination 
comprising potential risk factors for transition to psychosis including systematic assessment 
of psychopathological symptoms, neuropsychological examination, analyses of different 
blood parameters, resting state electroencephalography (EEG) and structural magnetic 
resonance imaging (MRI). All these examinations serve as well to exclude any organic 
reason leading to psychosis.  
The dissertation at hand addresses the topic of the hormone prolactin in relation to psychosis 
on one hand and on the other hand aims to elucidate whether there are any sex differences 
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regarding this specific hormone (prolactin), regarding cognitive functioning and regarding 
correlation of self- and observer-ratings of psychopathology. The role of prolactin in early 
psychosis is discussed in the first publication and the topic of possible sex differences is 
covered by all of the publications (1, 2 and 3) included in this dissertation.  
We used some additional exclusion criteria specifically for analysing prolactin values (first 
publication): All patients who had ever taken any antipsychotics or any prolactin-influencing 
medication (i.e. hormonal contraception) at the time of assessment were excluded. Likewise, 
all patients with a medical condition potentially influencing prolactin status, such as 
hypothyroidism or pituitary abnormalities were excluded.  
For the second publication (Sex differences in cognitive functioning in at-risk mental state for 
psychosis, first episode psychosis and healthy control subjects) a sample of HC from trade 
schools, hospital staff and through advertisements has been recruited. HC subjects with a 
current or former psychiatric disorder or neurological disease, serious medical condition, 
substance abuse, or a family history of psychiatric disorder were excluded (for more detailed 
information see methods section in respective publication). 
 
2 Theoretical Background 
2.1 The role of prolactin in emerging psychosis 
Prolactin is a polypeptide hormone involved in a broad spectrum of functions, including 
reproduction and lactation (Fitzgerald & Dinan, 2008). It is predominantly synthesized and 
secreted by lactotroph cells of the anterior pituitary gland. Prolactin release is stimulated by 
sucking but also by psychosocial stress (Fitzgerald & Dinan, 2008; Lennartsson & Jonsdottir, 
2011). There is compelling epidemiological evidence that psychosocial stress is implicated in 
the development of psychotic symptoms (van Winkel, Stefanis, & Myin-Germeys, 2008). A 
recent study found that the risk of developing psychosis increases with the number of life 
events experienced (Shevlin, Houston, Dorahy, & Adamson, 2008). Moreover, several 
studies have shown an association of environmental factors, which could be proxies for 
psychosocial stress, with psychosis (van Os, 2004; van Os, Hanssen, Bak, Bijl, & Vollebergh, 
2003; van Os, Pedersen, & Mortensen, 2004). More specifically, both growing up in an urban 
environment and having a migration background, which is associated with discrimination, 
increase the risk for psychosis (Cantor-Graae & Selten, 2005). Moreover, immediate stress is 
assumed to play a role in triggering psychosis. Previous research has shown an association 
between cortisol levels and severity of positive and nonspecific symptoms (Aiello, Horowitz, 
Hepgul, Pariante, & Mondelli, 2012; Holtzman et al., 2013; Walker et al., 2013). Stress is also 
thought to influence the volume of the pituitary gland, which was indicated by magnetic 
resonance imaging (MRI) studies. ARMS as well as FEP patients showed enlarged pituitary 
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gland volumes independent of antipsychotic treatment (Büschlen et al., 2011; Pariante et al., 
2005; Walter et al., 2014).  
The main regulatory mechanism acting on prolactin is the inhibition of prolactin synthesis by 
dopamine. Dopamine itself is synthesized in neurons of the hypothalamus and then secreted 
through portal blood into the anterior pituitary where it exerts its inhibitory actions on 
prolactin-producing cells through D2 receptors. Thus, dopamine is the main prolactin 
inhibiting factor (PIF; Fitzgerald & Dinan, 2008). On the other hand, the dopaminergic 
neurotransmission plays an important role in the pathophysiology of schizophrenic 
psychoses (Howes et al., 2009). This inference was made from the link between the 
antipsychotic efficacy of neuroleptic drugs and their affinity for the dopaminergic D2 receptor 
(Bennett, 1998). Consequently, hyperprolactinemia is often described as a side effect of 
antipsychotics in patients with schizophrenic psychoses (Peuskens, Pani, Detraux, & De 
Hert, 2014). Nonetheless, recent reports have described hyperprolactinemia also in 
antipsychotic-naïve FEP and ARMS patients. In these patients, hyperprolactinemia could be 
due to psychosocial stress (A. Riecher-Rössler et al., 2013) as stress is implicated in the 
development of psychotic symptoms (van Winkel et al., 2008) and known to stimulate 
prolactin synthesis and release (Lennartsson & Jonsdottir, 2011). Riecher-Rössler (2013) 
formulated the following hypothesis: ”It might be speculated that stress induced 
hyperprolactinemia plays a role in triggering the outbreak of acute psychotic symptomatology 
because hyperprolactinemia induces the production of PIF, which is more or less identical 
with dopamine”. Several studies found either elevated prolactin levels (above the reference 
level) or increased prolactin levels compared to a control group in antipsychotic-naïve FEP 
and schizophrenia patients (Aston et al., 2010; Gonzalez-Blanco et al., 2016; Petrikis et al., 
2016; A. Riecher-Rössler et al., 2013). Furthermore, even in ARMS patients a high 
proportion of hyperprolactinemia or increased prolactin levels compared to healthy controls 
(HC) have been reported (Aston et al., 2010; Labad et al., 2015). In addition, a study 
conducted in patients with pituitary microadenoma showed significantly higher prolactin 
serum levels in antipsychotic-naïve patients with a pituitary microadenoma with psychosis 
than in patients with a pituitary microadenoma without psychosis (Cheng, Wen, Tang, Zhong, 
& Gan, 2013).  
One main goal of this work (first publication) was to further explore the role of prolactin in 
emerging psychosis. Therefore we formulated the following hypotheses based on previous 
findings: We expected I) increased frequencies of hyperprolactinemia in ARMS and FEP 
patients (Aston et al., 2010) and II) higher prolactin levels in FEP as compared to ARMS 
patients. As prolactin is also a stress hormone and stress is thought to be associated with  
psychopathological symptoms (Aiello et al., 2012; Holtzman et al., 2013; Walker et al., 2013) 
we hypothesized to find III) a positive association of prolactin with psychopathological 
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symptoms as measured with the Brief Psychiatric Rating Scale Expanded Version (BPRS-E; 
Lukoff, Nuechterlein, & Ventura, 1986; Ventura et al., 1993). IV) According to the hypothesis 
of stress induced prolactin release leading to dopamine increase and thereby triggering the 
outbreak of psychosis (see above) we also hypothesized higher baseline prolactin levels 
being predictive of transition to psychosis in ARMS patients.  
 
2.2 Sex differences in schizophrenia, first episode psychosis and at-risk mental state for 
psychosis patients 
Sex has been shown to impact on brain anatomy and cognitive functioning through a 
complex interplay of biological and psychosocial factors. Given that differences between 
women and men with schizophrenia have been described regarding many aspects of the 
illness, including age of onset, symptomatology, treatment response, course and 
psychosocial outcome (Abel, Drake, & Goldstein, 2010; Ochoa, Usall, Cobo, Labad, & 
Kulkarni, 2012; A Riecher-Rössler, Pflueger, & Borgwardt, 2010), it seems obvious that this 
topic is of high importance. One of the most consistent findings is that women are older than 
men when first symptoms arise (Eranti, MacCabe, Bundy, & Murray, 2013; Häfner et al., 
1994). Furthermore, women seem to have a more favourable outcome than men (Ochoa et 
al., 2012; A. Riecher-Rössler & Rössler, 1998). Therefore, the decision was made to have a 
closer look at possible sex differences in some of the parameters, which are assessed in the 
FePsy-study. A better knowledge of specific sex differences may elucidate pathogenic 
mechanisms underlying schizophrenia that are specific or unequally distributed in women 
and men, potentially leading to improved treatment strategies.  
2.2.1 Sex differences in normalized prolactin levels 
As described above, elevated prolactin serum levels have been described in antipsychotic-
naïve ARMS and FEP patients and are supposed to play a role in emerging psychosis. 
Prolactin reference levels are different for healthy men and women with higher normal levels 
in women. Nevertheless, independent of normal biological variation, sex differences in 
prolactin levels have been described in a metaanalysis of Gonzalez-Blanco showing more 
pronounced group differences in men (between patients and controls) than in women. 
Therefore, we wanted to analyse possible sex differences in prolactin levels in our sample 
and hypothesized to find more elevated prolactin levels in men than in women (Gonzalez-
Blanco et al., 2016). 
2.2.2 Sex differences in cognitive functioning  
The impairment of cognitive functioning is recognized as a core feature of schizophrenia and 
is closely related to the outcome of the disease (Kahn & Keefe, 2013; Palmer, Dawes, & 
Heaton, 2009). It is not only present in patients with schizophrenic psychoses, but already 
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evident in individuals with an ARMS for psychosis (Hauser et al., 2017; Pflueger, 
Gschwandtner, Stieglitz, & Riecher-Rossler, 2007). In addition, it has been shown that ARMS 
individuals with later transition to psychosis perform worse on tests measuring verbal fluency 
and memory (Hauser et al., 2017) and speed of information processing (Brewer et al., 2005; 
A. Riecher-Rössler, Pflueger, et al., 2009) compared to those without transition. It has been 
consistently reported that prediction of psychosis can be improved by considering 
neurocognitive performance measures (Koutsouleris et al., 2012; A. Riecher-Rössler, 
Pflueger, et al., 2009; Studerus, Papmeyer, & Riecher-Rössler, 2014). 
Sex differences in cognitive functioning in healthy individuals are well known. Generally, 
women tend to perform better than men in tasks measuring verbal abilities, whereas the 
opposite is true for visuo-spatial skills (Halari et al., 2005; Halpern, 2004; Miller & Halpern, 
2014). In schizophrenia patients, there are similar differences in cognitive functioning 
between men and women. Many studies have shown a sex difference in schizophrenia 
patients in the domain of verbal learning and memory with better performance in women 
(Albus et al., 1997; Bozikas et al., 2010; Goldstein et al., 1998; Han et al., 2012; Hoff et al., 
1998; Longenecker, Dickinson, Weinberger, Elvevag, & Dickinson, 2010; Vaskinn et al., 
2011) which is line with findings in HC. However, results in other cognitive domains 
(executive functions, attention, working memory and IQ) have been largely inconsistent. This 
could be due to different patient groups used (chronic schizophrenia patients vs. first episode 
psychosis patients), medication, neuropsychological tasks for assessing the same cognitive 
domain and also varying statistical power. Only one study has been conducted in ARMS 
patients. In this study, men as compared to women showed a better performance in picture 
completion (WISC-III and WAIS-III;  Walder, Mittal, Trotman, McMillan, & Walker, 2008). No 
study has yet analysed sex-related cognitive performance differences in ARMS and FEP 
patients together. In consideration of the fact that cognitive impairment is recognized as core 
feature of schizophrenia, it is conceivable that sex differences in cognitive functioning 
developing over different stages of the disease could give rise to new hypotheses indicating 
pathogenic mechanisms of the illness. Therefore, we wanted to study sex differences in 
cognitive functioning in ARMS, FEP and HC subjects and also whether sex differences vary 
between the investigated groups. Based on previous research, a better performance of 
women in the domain of verbal learning and memory was expected in all groups. 
2.2.3 Influence of sex on the correlation between self- and observer-ratings of 
psychopathology 
Self-rating scales are easily applicable and are not time-consuming. In contrast, observer-
rating scales are more time consuming and need a well-trained professional (Hartmann, 
Fritzsche, & Lincoln, 2013) but considered objective measures of psychopathological 
symptoms in patients with psychotic disorder (Niv, Cohen, Mintz, Ventura, & Young, 2007). 
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Yet, it is not clear whether psychosis patients report their symptoms accurately which would 
be a requirement for coherent self- and observer-rating. It has long been assumed that self-
ratings are not reliable in schizophrenia patients because they have many features like poor 
insight, denial, delusions and cognitive deficits that probably make a self-rating of their 
symptoms impossible or at least hamper it (Amador & David, 1998). However, previous 
empirical work (6 different studies) points towards a good agreement between self- and 
observer-rating of positive psychotic symptoms  (Hamera, Schneider, Potocky, & Casebeer, 
1996; Iancu, Poreh, Lehman, Shamir, & Kotler, 2005; Lincoln, Ziegler, Lullmann, Muller, & 
Rief, 2010; Liraud, Droulout, Parrot, & Verdoux, 2004; Preston & Harrison, 2003). Only three 
studies did not support this finding and reported poor correlations (Biancosino et al., 2007; 
Lasalvia, Ruggeri, & Santolini, 2002; Morlan & Tan, 1998).  
Concerning negative symptoms, correlations between self- and observer-ratings seem to be 
inconsistent (Bell, Fiszdon, Richardson, Lysaker, & Bryson, 2007; Bottlender et al., 2003; 
Hamera et al., 1996; Iancu et al., 2005; Liraud et al., 2004; Preston & Harrison, 2003).  
The concordance between self- and observer-ratings regarding depressive symptomatology 
in psychosis patients was pretty good in most of the studies (Biancosino et al., 2007; Morlan 
& Tan, 1998; Rush et al., 2006). 
The existing studies vary in some factors such as disease stage and distribution between the 
sexes, which potentially can influence the agreement between self- and observer-rating. In a 
previous study, FEP patients were found to have more impaired insight than ARMS patients 
(Lappin et al., 2007) and therefore it is reasonable to assume that ARMS patients would also 
show a higher agreement between self- and observer-rating than FEP patients.    
As already mentioned above, sex differences in schizophrenia have been described in many 
aspects of the illness (Abel et al., 2010; Ochoa et al., 2012; A. Riecher-Rössler & Häfner, 
2000) but it is not clear if sex also influences the agreement between self- and observer-
rating. In mixed patient samples or patients with depression some studies point towards a 
higher agreement regarding affective symptoms in women (Jolly, Wiesner, Wherry, Jolly, & 
Dykman, 1994; Shain, Naylor, & Alessi, 1990). As opposed to the precedent studies, there 
are also studies conducted with samples of psychotic and non-psychotic major depression 
patients which do not support a better agreement regarding affective symptoms in women 
(Domken, Scott, & Kelly, 1994; Rush et al., 2006). Only one study specifically investigated 
the influence of sex on the agreement between self- and observer-rating of positive psychotic 
symptoms in schizophrenia patients and could not show a difference between men and 
women (Lincoln et al., 2010).  
The goal of the third study was thus to compare self- and observer-ratings of affective, 
negative and positive symptoms in ARMS and FEP patients and to investigate whether the 
agreement was dependent on disease stage (ARMS, FEP) and sex (men, women). Based 
17 
 
on the above mentioned previous research we expected a higher association between self- 
and observer-rating in ARMS as compared to FEP patients and a stronger correlation in 
women as compared to men. 
3 Empirical Studies 
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Riecher-Rössler A., (2017), Sex differences in prolactin levels in emerging psychosis: 
Indication for enhanced stress reactivity in women. Schizophrenia Research. [Epub ahead 
of print] 
Ittig S., Studerus E., Papmeyer M., Uttinger M., Koranyi S., Ramyead A., Riecher-Rössler A., 
(2014), Sex differences in cognitive functioning in at-risk mental state for psychosis, first 
episode psychosis and healthy control subjects. Eur Psychiatry., 30(2): 242-50. 
Spitz A., Studerus E., Koranyi S., Rapp C., Ramyead A., Ittig S., Heitz U., Uttinger M. and 
Riecher-Rössler A., (2015), Correlations between self-rating and observer-rating of 
psychopathology in at-risk mental state and first-episode psychosis patients: influence of 
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Background:Hyperprolactinemia is a known side effect of antipsychotics. In recent reports it has also been shown
in antipsychotic-naïve at-risk mental state (ARMS) and ﬁrst-episode psychosis (FEP) patients. Prolactin is not
only involved in reproduction and lactation, but is also synthesized in response to stress. As stress is thought
to play an important role in the onset and relapse of schizophrenia, the aim of this study was to further elucidate
the inﬂuence of prolactin in emerging psychosis.
Methods: The data analysed in this study were collected within the prospective Früherkennung von Psychosen
(FePsy) study. Blood sample collection took place under standardized conditions between 8 and 10 am after
an overnight fast and 30 minutes of rest. All patients were antipsychotic-naïve and did not take any prolactin
inﬂuencing medication.
Results: Our sample consisted of 116 antipsychotic-naïve ARMS and 49 FEP patients. Hyperprolactinemia was
shown in 32% of ARMS and 35% of FEP patients. After correction for the normal biological variation between
the sexes, we still found higher average prolactin levels in female than in male patients (β= 0.42; t = 2.47;
p= 0.01) but no difference in prolactin levels between ARMS and FEP patients (β=−0.05; t =−0.30; p=
0.76). The survival analysis revealed no signiﬁcant predictive value for prolactin levels to predict transition to
psychosis.
Conclusion:Ourﬁndings support a possible role of prolactin in emerging psychosis and it could be speculated that
stress, which can induce hyperprolactinemia, has a stronger effect on women than on men in emerging
psychosis.
© 2017 Published by Elsevier B.V.
Keywords:
Schizophrenia
Blood levels
Stress hormone
Gender differences
Clinical high-risk
1. Introduction
Prolactin is a polypeptide hormone that is predominantly synthe-
sized and secreted by lactotroph cells of the anterior pituitary gland.
While its main function is to elicit lactation in mammals (Fitzgerald
and Dinan, 2008), it is also involved in a broad spectrum of functions
beyond reproduction and lactation. Most importantly, it is also released
in response to psychosocial stress (Fitzgerald and Dinan, 2008;
Lennartsson and Jonsdottir, 2011). There is compelling epidemiological
evidence that psychosocial stress is implicated in the development of
psychotic symptoms (Aiello et al., 2012; van Winkel et al., 2008).
Previous research has shown an association between cortisol levels
and severity of positive and nonspeciﬁc symptoms (Aiello et al., 2012;
Holtzman et al., 2013; Walker et al., 2013), as well as correlations
between the stress hormone prolactin and psychopathological symp-
toms (Rajkumar, 2014).
Themain regulatorymechanism acting on prolactin is the inhibition
of prolactin synthesis by dopamine. Dopamine itself is synthesized in
neurons of the hypothalamus and then secreted through portal blood
into the anterior pituitary where it exerts its inhibitory actions on
prolactin-producing cells through D2 receptors. Dopamine is thus the
main prolactin inhibiting factor (PIF) (Fitzgerald and Dinan, 2008). On
the other hand, dopaminergic neurotransmission plays an important
role in the pathophysiology of schizophrenic psychoses (Howes et al.,
2009) which was inferred from the link between the antipsychotic
efﬁcacy of neuroleptic drugs and their afﬁnity for the dopaminergic D2 re-
ceptor (Bennett, 1998). Hence, hyperprolactinemia is often described as a
side effect of antipsychotics in patients with schizophrenic psychoses
(Peuskens et al., 2014). However, there have also been recent reports on
hyperprolactinemia in antipsychotic-naïve FEP and ARMS patients.
Hyperprolactinemia in these patients could probably be explained by
psychosocial stress (Riecher-Rössler et al., 2013), as it is implicated in
the development of psychotic symptoms (van Winkel et al., 2008) and
Schizophrenia Research xxx (2017) xxx–xxx
⁎ Corresponding author at: University of Basel Psychiatric Hospital, Center for Gender
Research and Early Detection, Kornhausgasse 7, 4051 Basel, Switzerland.
E-mail address: anita.riecher@upkbs.ch (A. Riecher-Rössler).
SCHRES-07173; No of Pages 6
http://dx.doi.org/10.1016/j.schres.2017.02.010
0920-9964/© 2017 Published by Elsevier B.V.
Contents lists available at ScienceDirect
Schizophrenia Research
j ourna l homepage: www.e lsev ie r .com/ locate /schres
Please cite this article as: Ittig, S., et al., Sex differences in prolactin levels in emerging psychosis: Indication for enhanced stress reactivity in
women, Schizophr. Res. (2017), http://dx.doi.org/10.1016/j.schres.2017.02.010
19
known to stimulate prolactin synthesis and release (Lennartsson and
Jonsdottir, 2011). Riecher-Rössler et al. (2013) suggested that stress in-
duces hyperprolactinemia and the resulting increase of dopamine in psy-
chosismight be, at least in part, a regulatorymechanism to down regulate
prolactin. The European First Episode Schizophrenia Trial (EUFEST)
(Riecher-Rössler et al., 2013) found elevated prolactin levels in 40.5% of
antipsychotic-naïve FEP patients. In a further study by Aston et al.
(2010) hyperprolactinemia was found in 33.3% of antipsychotic-naïve
FEP patients and even in 23.8% of ARMS patients. A recent meta-analysis
(Gonzalez-Blanco et al., 2016) reported higher prolactin levels in antipsy-
chotic-naïve male and female patients with schizophrenia compared to
control groups of the same gender, although the effect was much more
pronounced inmen than inwomen. A recent study also foundhigher pro-
lactin serum levels in drug naïve newly diagnosed patients with schizo-
phrenia and other psychotic disorders compared to HC (Petrikis et al.,
2016). Furthermore, Labad et al. (2015) showed that ARMS patients
who later made a transition to psychosis (ARMS-T) had higher prolactin
levels than those who did not (ARMS-NT). Moreover, one study conduct-
ed in patients with pituitary microadenoma (Cheng et al., 2013) showed
signiﬁcantly higher prolactin serum levels in antipsychotic-naïve patients
with a pituitary microadenomawith psychosis than in patients with a pi-
tuitary microadenoma without psychosis. All these ﬁndings provide fur-
ther evidence for an association of elevated prolactin levels and psychosis.
To further elucidate the role of prolactin in emerging psychosis we
formulated the following hypotheses based on previous ﬁndings. We
expected I) increased frequencies of hyperprolactinemia in ARMS and
FEP patients (Aston et al., 2010), II) higher prolactin levels in FEP as
compared to ARMS patients, and III) more elevated prolactin levels in
men than in women (Gonzalez-Blanco et al., 2016). Moreover, as pro-
lactin is also a stress hormone and stress is thought to have an inﬂuence
on psychopathology (Aiello et al., 2012; Holtzman et al., 2013; Walker
et al., 2013) we hypothesized to ﬁnd IV) a positive association of prolac-
tin with psychopathological symptoms and V) higher baseline prolactin
levels being predictive of transition to psychosis in ARMS patients.
2. Methods
2.1. Setting and recruitment
The data analysed in this study were collected within the prospec-
tive Früherkennung von Psychosen (FePsy) study, which aims to im-
prove the early detection of psychosis. A more detailed description of
the overall study design can be found elsewhere (Riecher-Rössler et
al., 2007; Riecher-Rössler et al., 2009). Participants were recruited for
the study via the FePsy Clinic at the Psychiatric University Outpatient
Department of the Psychiatric University Hospital Basel, which was set
up speciﬁcally to identify and treat individuals in the early stages of
emerging psychosis.
The studywas approved by the ethics committee of the University of
Basel and all participants provided written informed consent.
2.2. Screening procedure
Screening was performed with the Basel Screening Instrument for
Psychosis (Riecher-Rössler et al., 2008). This instrument allows the rat-
ing of individuals regarding the inclusion/exclusion criteria correspond-
ing to the Personal Assessment and Crisis Evaluation (PACE) criteria
(Yung et al., 2007; Yung et al., 1998) and has been shown to have a
good interrater reliability (κ=0.67) for the assessment of themain out-
come category “at risk for psychosis” and a high predictive validity
(Riecher-Rössler et al., 2008). Individuals were classiﬁed as being in
an ARMS for psychosis, having a FEP, or being not at risk for psychosis
(usually other psychiatric disorders).
For this study we included all ARMS and FEP patients that were re-
cruited for the FePsy study from March 1, 2000 to February 29, 2016
who had undergone prolactin measurement. We excluded all patients
whohad ever taken antipsychotics or any prolactin-inﬂuencingmedica-
tion at the time of assessment (i.e. hormonal contraception). Likewise,
we excluded all patients with a medical condition potentially inﬂuenc-
ing prolactin status, such as hypothyroidism or pituitary abnormalities
or in whom blood sampling and psychopathological assessment were
N60 days apart.
All ARMS patients were followed-up at regular intervals for up to
5 years (in the ﬁrst year monthly, second and third year 3-monthly
and the last two years every year) (Riecher-Rössler et al., 2009) in
order to distinguish those who later transitioned to frank psychosis
(ARMS-T) from those who did not (ARMS-NT) using the transition
criteria of Yung et al. (1998).
2.3. Prolactin measurement
The patients were asked to avoid stress, sports, physical activity,
stimulation of breast and smoking during the last 12 h before blood
sampling. Blood sample collection took place between 8 and 10 am
after overnight fast and 30 min of rest (7.5 ml whole blood without
any additions).
The ElectroChemiLuminescence ImmunoAssay “ECLIA” (Ref. Num-
ber 03203093 190, Roche Diagnostics GmbH D-68305 Mannheim)
was used to measure prolactin levels. The method has been standard-
ized against the 3rd IRP WHO Reference Standard 84/500 and
hyperprolactinemia in this reference is deﬁned as a value above the
97.5th percentile, that is N324 mU/l in men and N496 mU/l in women.
2.4. Psychopathological assessment
The Brief Psychiatric Rating Scale Expanded Version (BPRS-E)
(Lukoff et al., 1986; Ventura et al., 1993)wasused to assess positive psy-
chotic symptoms, symptoms of depression/anxiety, negative symptoms
as well as symptoms of activation as deﬁned by Velligan et al. (2005).
2.5. Statistical analyses
All data were analysed using the R environment for statistical com-
puting (R Core Team, 2015). Differences in sociodemographic and clin-
ical characteristics between ARMS and FEP patients were tested with t
and χ2 tests. Prolactin was analysed both on a continuous and binary
scale (above reference range of corresponding sex vs. within normal
range) using linear and logistic regression models, respectively. In
both models, prolactin served as dependent variable and group (ARMS
vs. FEP) and sex (men, women) as independent variables. The models
also included an interaction term between group and sex. When
analysed on a continuous scale, prolactin values were ﬁrst log-trans-
formed (to accommodate positive skew) and then normalized for men
and women separately based on the log transformed reference ranges
for healthymen andwomen. Themeans and SDs of the log transformed
normative samples for men and women were calculated by taking the
means of log transformed upper and lower bounds of the reference
ranges and by dividing the differences between log transformed upper
and lower bounds of the reference ranges by 3.92, respectively. Thus,
the normal sex difference in prolactin seen in healthy individuals was
partialled out from our continuous prolactin measure before inclusion
to the models.
To analyse the relationship between prolactin, group (ARMS, FEP)
and psychopathology, linear regression models were performed with
the four BPRS composite scores (see psychopathological assessment)
serving as dependent variables. All continuous variables were centered
and all analyses were performed with and without covariates (age and
current use of antidepressants). Furthermore, p-values were adjusted
for multiple testing using the Benjamini-Hochberg method (Benjamini
and Hochberg, 1995).
Finally, to test whether prolactin is predictive of later transition to
psychosis (event) in the ARMS group and whether its association with
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later transition is different formen andwomen, survival analysis using a
Cox proportional hazard model was performed. For this purpose, all
ARMS patients regardless of their follow-up duration were included in
the analyses since survival analyses take into account censored observa-
tions (no event during observation time). The Cox regression model in-
cluded time to transition as dependent variable and prolactin (log-
transformed and normalized) and sex and their interaction as predic-
tors. Age and current use of antidepressants served as covariates in
our model.
3. Results
3.1. Sample description
181 ARMS and 132 FEP patients were recruited for the FePsy study
from March 1, 2000 to February 29, 2016. Because of missing prolactin
measurements we excluded 46 ARMS and 53 FEP patients. Further, we
excluded 19 ARMS and 30 FEP patients either because of lifetime anti-
psychotic medication, current hormonal contraception, any other cur-
rent prolactin inﬂuencing medication or because blood sampling
and psychopathological assessment were N60 days apart. Thus, we
performed the analyses on the remaining sample consisting of 116
ARMS and 49 FEP patients. The excluded individuals did not differ
from those included with regard to sex, age, years of education and
BPRS total score. The mean difference between the assessment of the
BPRS and blood sample collection was 8.18 days (S.D. = 9.52).
Sociodemographic as well as clinical characteristics of the included
individuals are presented in Table 1.
3.2. Hyperprolactinemia in ARMS and FEP patients
Hyperprolactinemia, i.e. blood levels higher than the normal range,
was present in 32% of ARMS (28% of men and 41% of women) and 35%
of FEP patients (26% of men, 53% of women) (Table 2).
3.3. Effect of sex and patient group on prolactin levels
When prolactin was analysed on a continuous scale, there was a
signiﬁcant main effect of sex (β=0.35; t= 2.47; p=0.01) but no sig-
niﬁcant main effect of group (ARMS vs. FEP) (β=−0.04; t =−0.30;
p = 0.76) and no signiﬁcant interaction between sex and group
(β=−0.07; t=−0.48; p= 0.63). The main effect of sex was due to
signiﬁcantly higher average prolactin levels in female than in male pa-
tients even after correction for the normal sex difference in prolactin
levels of healthy individuals.
Prolactin values in ARMS and FEP patients subdivided in men and
women are displayed in Fig. 1. For the means, S.D., median and range
of the normalized prolactin values per patient group (ARMS/FEP) and
sex (men/women) see Table 2.
When prolactinwas analysed on a binary scale (Hyperprolactinemia
vs. normal prolactin values), there was again a signiﬁcantmain effect of
sex (β= 0.44; z= 2.25; p= 0.02), no signiﬁcant main effect of group
(β=−0.10; z =−0.53; p = 0.60) and no signiﬁcant interaction be-
tween sex and group (β= −0.14; z =−0.74; p = 0.46), indicating
that hyperprolactinemia was more frequent in female than in male pa-
tients independent of diagnostic group.
When repeating the analyses with covariates age and antidepres-
sants the results did not change.
3.4. Effects of prolactin and patient group on psychopathology
For each BPRS subscale (Total, Psychosis/Thought Disturbance, De-
pression/Anxiety, Negative Symptoms, Activation) there was a signiﬁ-
cant main effect of patient group, which was due to more severe
psychopathology in FEP compared to ARMS patients (see Table 3).
However, therewere no signiﬁcantmain effects of prolactin on these
BPRS subscales and no signiﬁcant interactions between prolactin and
diagnostic group (ARMS/FEP) after correction for multiple testing (see
Table 3, also for uncorrected values). When repeating the analyses
Table 1
Socio-demographic and clinical sample characteristics.
Total group ARMS FEP p-Value
N = 165 N = 116 N = 49
Gender 1.000
Women 49 (29.7%) 34 (29.3%) 15 (30.6%)
Men 116 (70.3%) 82 (70.7%) 34 (69.4%)
Age 26.1 (6.90) 25.1 (6.16) 28.4 (7.99) 0.011*
Years of education 11.6 (2.97) 11.5 (2.90) 11.7 (3.14) 0.774
Antidepressants ever 48 (29.1%) 42 (36.2%) 6 (12.2%) 0.004**
Antidepressants currently 41 (24.8%) 35 (30.2%) 6 (12.2%) 0.025*
Anxiolytics ever 31 (18.8%) 25 (21.6%) 6 (12.2%) 0.238
Anxiolytics currently 26 (15.8%) 20 (17.2%) 6 (12.2%) 0.568
BPRS Depression/Anxiety 9.38 (3.77) 8.81 (3.46) 10.8 (4.17) 0.007**
BPRS Psychosis/Thought Disturbance 7.56 (3.77) 6.05 (2.30) 11.3 (4.11) b0.001***
BPRS Activation 5.79 (2.33) 5.39 (1.84) 6.75 (3.04) 0.008**
BPRS Negative Symptoms 5.33 (2.73) 4.95 (2.44) 6.26 (3.18) 0.017*
BPRS Total Score 42.0 (12.3) 37.8 (9.30) 52.4 (12.5) b0.001***
ARMS = at-risk mental state; FEP = ﬁrst episode psychosis; BPRS = brief psychiatric rating scale; *p b 0.05; **p b 0.01, ***p b 0.001; continuous variables are described by means and
standard deviation in parentheses.
Table 2
Hyperprolactinemia and normalized prolactin values in antipsychotic-naive ARMS and FEP patients.
ARMS FEP
Men (n = 82) Women (n = 34) Total (n = 116) Men (n = 34) Women (n = 15) Total (n = 49)
Proportion of patients with hyperprolactinemia, n (%) 23 (28) 14 (41) 37 (32) 9 (26) 8 (53) 17 (35)
Prolactin normalized
Mean ± S.D. 1.201 ± 1.481 1.766 ± 1.451 1.366 ± 1.489 1.150 ± 1.695 1.989 ± 1.601 1.407 ± 1.696
Median 1.188 1.723 1.355 0.787 2.043 1.507
Range −2.526–5.103 −1.104–4.476 −2.526–5.103 −2.398–5.265 −0.962–4.104 −2.398–5.265
ARMS = at-risk mental state; FEP = ﬁrst episode psychosis.
S.D., standard deviation.
3S. Ittig et al. / Schizophrenia Research xxx (2017) xxx–xxx
Please cite this article as: Ittig, S., et al., Sex differences in prolactin levels in emerging psychosis: Indication for enhanced stress reactivity in
women, Schizophr. Res. (2017), http://dx.doi.org/10.1016/j.schres.2017.02.010
2
with the covariates age and antidepressants the results did not change
substantially (see Table 3).
3.5. Prolactin as predictor of transition to psychosis
To investigate if prolactin values can predict later transition to psy-
chosis and if the predictive value is different for men and women, we
conducted a survival analysis within the ARMS group (n=116, number
of events 23, follow-up duration ARMS-NT: mean = 2.99 years, SD =
0.19, follow-up duration ARMS-T: mean= 1.24, S.D. = 0.32). The anal-
yses revealed no signiﬁcant predictive value of prolactin levels and no
interaction effect with the variable sex (see Table 4).
4. Discussion
In this study, the role of prolactin was investigated in 116 antipsy-
chotic-naïve ARMS and 49 antipsychotic-naïve FEP patients. In line
with our hypothesis, we could replicate the ﬁnding of an increased
percentage of patients suffering from hyperprolactinemia in antipsy-
chotic-naïve ARMS and FEP patients even when blood was taken
under controlled conditions and rigorous exclusion criteria were ap-
plied. Furthermore, we found that prolactin was more increased in
women than in men after correction for the normal biological variation
between the sexes. Contrary to our hypotheses, we could not show a
difference in prolactin levels between ARMS and FEP patients; prolactin
was not signiﬁcantly associated with any BPRS subscale and none of
these associations were moderated by patient group (ARMS, FEP).
Moreover, prolactin was not a signiﬁcant predictor of transition to
psychosis.
While only 2.5% of people in the normal population are expected
to fulﬁl criteria for hyperprolactinemia according to our reference
standard, we found in our sample of antipsychotic-naïve ARMS
and FEP patients that 32% of ARMS and 35% of FEP suffered from
hyperprolactinemia. Similarly high proportions have been reported in
previous studies (Aston et al., 2010; Riecher-Rössler et al., 2013).
Hyperprolactinemia requires clinical attention because it can have se-
vere consequences, including amenorrhea, galactorrhea, an acceleration
of osteoporosis inwomen and a lack of libido and erectile dysfunction in
men (Rajkumar, 2014; Rubio-Abadal et al., 2016). These consequences
Fig. 1. Prolactin serum levels in ARMS and FEP patients subdivided by sex. The dotted
horizontal lines represent the upper and lower reference levels for men and women.
ARMS = at-risk mental state; FEP = ﬁrst episode psychosis.
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are often attributed to antipsychotics and can be a reason for non-compli-
ant behaviour. Thus, it is of utmost importance tomeasure prolactin levels
before treatment to reveal a possible pre-existing hyperprolactinemia.
Contrary to the meta-analysis of Gonzalez-Blanco et al. (2016) we
found higher normalized prolactin levels and more frequent
hyperprolactinemia in women than in men. Gonzalez-Blanco did only
include studies with a healthy control group and therefore disregarded
an important study in the ﬁeld. Riecher-Rössler and the EUFEST study
group (2013) found hyperprolactinemia to be present in 50% of antipsy-
chotic-naïve female FEP patients but only in 36.5% of antipsychotic-
naïve male FEP patients. Our ﬁnding of higher prolactin levels in
women is also supported by a study of Lennartsson and Jonsdottir
(2011) who demonstrated that women showed stronger prolactin re-
sponses to the Trier Social Stress Test (TSST; Kirschbaumet al., 1993), al-
beit only at a trend-level.
Our ﬁnding of a non-signiﬁcant difference in prolactin levels be-
tween ARMS and FEP patients is in agreement with the only other
study that compared prolactin levels between ARMS and FEP patients
(Montalvo et al., 2014). This could indicate that stress levels are not
higher in FEP than in ARMS patients. On the other hand, studies investi-
gating the stress hormone cortisol have reported higher levels in FEP
than in ARMS patients (Aiello et al., 2012; Holtzman et al., 2013;
Walker et al., 2013). In a similar vein, our ﬁnding of non-signiﬁcant as-
sociations between prolactin and BPRS subscales is difﬁcult to reconcile
with previous research which has shown an association between the
stress hormone cortisol and the severity of positive and nonspeciﬁc
symptoms (Aiello et al., 2012; Holtzman et al., 2013; Walker et al.,
2013). However, it is consistent with our ﬁnding of no difference in pro-
lactin levels between ARMS and FEP patients and with a study of
Shrivastava and Tamhane (2000)whodid notﬁndan association of pro-
lactin with BPRS (although their study had a small sample size: men;
N=19, women; N=8). Further studies are needed to clarify the asso-
ciation between prolactin and psychopathological symptoms.
Although we could not conﬁrm that prolactin is predictive of transi-
tion to psychosis, this result is consistent with Perkins et al. (2015) who
measured expression of plasma analytes reﬂecting inﬂammation,
oxidative stress, hormones and metabolism in a sample of 72 ARMS
patients and found that prolactin was not selected as a predictor of
transition to psychosis by a machine learning algorithm. However,
contradictory results were found by Labad et al. (2015). Therefore, on
the basis of the above described studies no deﬁnite conclusion can be
drawn.
A limitation of our study is that blood sampling did not take place on
the same day as the psychopathological assessment, and probably not at
time of peak symptom severity. Thus, prolactin levels may have not en-
tirely reﬂected stress levels at the time of psychopathological symptom
assessment. Future studies should also assess individual perceived
stress levels using, for example, the perceived stress scale (Cohen et
al., 1983), ideally at the time of psychopathological assessment and at
the time of blood sampling. The question whether elevated prolactin
levels are speciﬁc for emerging psychosis or rather generally associated
with emerging illness (e.g. depression etc.) still remains. Hence, recruit-
ment of control groups (e.g. depressive controls but also healthy con-
trols) would help to further clarify the role of prolactin in emerging
psychosis.
Taken together, our results provide further evidence for frequent
hyperprolactinemia in emerging psychosis and that this can be ob-
served in antipsychotic-naïve patients (ARMS, FEP). Moreover, women
in our patient sample (ARMS, FEP) had higher prolactin levels even
after correction for the normal biological variation, which potentially
provides an indication for a sex dependent stress reaction regarding
the hormone prolactin.
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1. Introduction
Sex differences in schizophrenia are described in almost all
aspects of the illness, including age of onset, symptomatology,
treatment response, time course and psychosocial outcome
[1,50,59]. One of the most consistent findings is that women are
older than men when first symptoms arise [16,24]. Furthermore,
women – especially at younger ages – seem to have a more
favourable outcome than men [50,55].
Closely related to the outcome of the disease is the impairment
of cognitive functioning which is recognized as a core feature of
schizophrenia [37,51] that is not only present in patients with
schizophrenic psychoses, but already evident in individuals with
an at-risk mental state (ARMS) for psychosis [9,20,53]. In addition,
it has been shown that ARMS individuals with later transition to
psychosis perform worse on tests measuring verbal fluency and
memory [9,18] and speed of information processing [12,56]
compared to those without transition. It has been consistently
reported that prediction of psychosis can be improved by
considering neurocognitive performance measures [40,56]. How-
ever, deficits in specific cognitive domains among ARMS and
schizophrenia patients are at least in part explained by differences
in IQ [31].
Sex differences in cognitive functioning are well known in
healthy individuals. In general, women tend to perform better than
men in tasks measuring verbal abilities, whereas the opposite is
true for visuo-spatial skills [25,26,28,47]. Kimura suggested that
tasks measuring verbal memory account for the most prominent
sex differences [38].
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Differences in cognitive functioning between men and women
have also been reported in schizophrenia patients. Many studies
have shown that women with schizophrenia perform better than
men with schizophrenia in the domain of verbal learning and
memory [3,11,22,27,32,45,65,72], which is in line with findings in
healthy controls (HC). In other cognitive domains, however, results
have been largely inconsistent. In the domain of executive
functions, two studies have demonstrated that women with
schizophrenia perform better as compared to men with schizo-
phrenia [22,61], two studies showed a worse performance of
female patients as compared to male patients [5,32] and three
studies did not find any performance differences [3,11,42]. In the
domain of attention, two studies showed a better performance of
women in relation to men with schizophrenia [22,72], one showed
a worse performance of female patients [52] and five studies could
not detect any sex differences [3,11,21,27,65]. With regard to
working memory, one study found that women with schizophrenia
perform worse, while three studies did not detect any performance
differences. Interestingly, when comparing clinical with healthy
control samples, Longenecker et al. reported an interaction effect in
the working memory domain: Men with schizophrenia failed to
exhibit the sex advantage during a working memory task which
was evident in the healthy control sample [45]. In relation to IQ
estimates, three studies out of four showed an equal performance
for both sexes of schizophrenia patients [3,8,21]. For speed of
processing, there is one study which showed a better performance
for women [65] and one study, which depicted no sex difference in
schizophrenia patients [11]. Only one study has been conducted
with ARMS patients showing a better performance of men
compared to women in picture completion (WISC-III and WAIS-
III) [68]. These largely inconsistent findings could be due to using
different patient groups (FEP, first episode schizophrenia, or
chronic patients), medication, neuropsychological tasks for asses-
sing the same cognitive domain and varying statistical power
(mean sample size = 140; range: 31–360).
Furthermore, no study has yet analysed sex-related cognitive
performance differences in ARMS individuals and first episode
psychosis (FEP) patients together. Since cognitive impairment is
recognized as a core feature of schizophrenia, sex differences in
cognitive functioning developing over different stages of the
disease could give rise to new hypotheses explaining pathogenic
mechanisms of the illness. Thus, the aim of the present study was
to investigate sex differences in cognitive functioning in ARMS, FEP
and HC subjects and whether sex differences vary between the
examined groups. Based on the above-cited studies, we expected a
better performance of women in the domain of verbal learning and
memory in all groups.
2. Methods
2.1. Setting and recruitment
The neuropsychological data analysed in this study were
collected within the prospective Fru¨herkennung von Psychosen
(FePsy) study, which aims to improve the early detection of
psychosis. A more detailed description of the overall study design
can be found elsewhere [57,56]. Participants were recruited for the
study via the FePsy Clinic at the Psychiatric University Outpatient
Department of the Psychiatric University Clinics Basel, which was
set up specifically to identify and treat individuals in the early
stages of psychosis.
We recruited a sample of HC from trade schools, hospital staff
and through advertisements. HC subjects with a current or former
psychiatric disorder or neurological disease, serious medical
condition, substance abuse, or a family history of psychiatric
disorder were excluded.
The study was approved by the ethics committee of the University
of Basel and all participants provided written informed consent.
2.2. Screening procedure
Screening was performed with the Basel Screening Instrument
for Psychosis [58]. This instrument allows the rating of individuals
regarding the inclusion/exclusion criteria corresponding to the
Personal Assessment and Crisis Evaluation (PACE) criteria [70,71]
and has been shown to have a good interrater reliability (k = 0.67)
for the assessment of the main outcome category ‘‘at-risk for
psychosis’’ and a high predictive validity [58]. Individuals were
classified as being in an ARMS for psychosis, having a FEP, or being
not at-risk for psychosis (usually other psychiatric disorders). We
included ARMS, FEP as well as a sample of HC in the present study.
2.3. Neuropsychological assessment
All neuropsychological assessments were conducted by psy-
chologists and well-trained, supervised advanced psychology
students. The test battery covered the following domains: general
intelligence, executive functions, working memory, attention,
verbal learning and memory [57,56].
General intelligence was estimated with the Mehrfachwahl-
Wortschatz Test (MWT-A) [41] and the Leistungspru¨fsystem,
Scale 3 [34], which are well established German intelligence scales
for assessing verbal and non-verbal (abstract reasoning) abilities.
Executive functions were assessed with the Tower of Hanoi
(ToH) [19], Wisconsin Card Sorting Test (WCS) [14,30], and Go/No-
Go subtest of the Test of Attentional Performance (TAP) [73].
Working memory was measured with the 2-back task of the
TAP [73] and vigilance with the Continuous Performance Test (CPT-
OX) [60].
Verbal learning and memory were assessed with the California
Verbal Learning Test (CVLT) [13].
For the Go/No-Go subtest and the 2-back task of the TAP as well
as for the CPT-OX test that requires subjects to discriminate
between two possible stimuli, we used the Signal Detection Theory
(SDT) to measure performance in terms of ‘‘response bias’’ and
‘‘sensitivity’’. Response bias reflects the tendency to respond with
yes and was quantified by the measure c, whereas sensitivity
indicates the degree of overlap between the signal and the noise
distributions and was quantified by the measure d0. Both measures
were calculated according to the formulas provided by Wright [69]
using the R package SDTALT [69]. The main advantage of using SDT
measures is the separation of response bias and sensitivity [62].
A summary cognitive score was calculated by performing a
principal component analysis on the test scores of the above-
described tasks and extracting the factor scores of the first
principal component. Thus, test scores were integrated in the
summary score with different weights, depending on how much
they loaded on the first principal component. The first principal
component explained 22% of the total variance.
2.4. Psychopathological assessments
Positive psychotic symptoms (i.e., hallucinations, suspicious-
ness, unusual thought content and conceptual disorganisation)
were assessed with the Brief Psychiatric Rating Scale (BPRS)
[46,66] and negative symptoms with the Scale for the Assessment
of Negative Symptoms (SANS) [4].
2.5. Statistical analyses
All data were analysed using the R environment for statistical
computing [63]. Differences in sociodemographic and clinical
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characteristics between men and women within each diagnostic
group (ARMS, FEP, HC and total group) were tested with t and x2
tests.
The following procedure was applied to investigate the effects of
sex (men, women) and diagnostic group (ARMS, FEP, HC) on
cognitive functioning. All of the 25 dependant variables, reflecting
cognitive functioning were screened for outliers. Values that were
3 standard deviations above or below the mean were treated as
missing if they could be attributed to misunderstanding of
instructions or truncated (i.e., replaced by the mean ! 3 standard
deviations) if no obvious cause for their emergence could be found. The
Box-Cox transformation [10] was applied to the outcome measures,
which did not conform to assumptions of normality and/or homo-
geneity of variance. The Box-Cox procedure automatically selects
exponential transformations that are optimal with regard to normal-
izing distributions and equalizing variances (Supplementary Table 1).
Since some of the outcome measures contained missing data
(Supplementary Table 1), we next performed multiple imputation
(MI) using the Multivariate Imputation by Chained Equations
software [64]. MI is considered the method of choice of handling
complex incomplete data problems because it yields unbiased
parameter estimates and standard errors under a missing at
random (MAR) or missing completely at random (MCAR) missing
data mechanism and maximizes statistical power by using all
available information [15]. Although the MAR or MCAR assump-
tion is not directly testable [54], it was considered plausible in the
present situation because the variables with the highest propor-
tion of missing values, such as those of the CVLT, resulted from
changes in the study design over the years and so the probability of
being missing was unlikely to be directly dependent on the missing
values themselves.
We generated 100 imputations of the missing values such that
100 completed datasets were obtained to protect against a
potential power falloff from a too small number of imputations
[23]. The analyses of interest were then conducted in each
completed data set and parameter estimates were pooled
according to Rubin’s rules [44].
Analyses of covariance models (ANCOVA) were applied to
evaluate the main effects of sex and group (ARMS, FEP, HC) as well
as their interactions on cognitive functioning. We included sex and
diagnostic group (ARMS, FEP, HC) as between subject factors and
influence of age, years of education and use of antipsychotics as
covariates. In case of significant interaction between sex and
diagnostic group, sex differences were explored within each
diagnostic group separately. The results are presented with and
also without correction for multiple testing. Each table contains a
column with the uncorrected and a column with the corrected P-
values (Benjamini’s and Hochberg’s correction [7]).
3. Results
3.1. Sample description
Hundred and thirty-six ARMS individuals and 104 FEP patients
were recruited for the FePsy study from March 1st, 2000 to
November 1st, 2013. We also recruited a sample of 97 HC
participants. We excluded 18 ARMS, 16 FEP and 11 HC because
their cognitive performance measures were not assessed.
Thus, we performed the analysis on the remaining sample
consisting of 118 ARMS, 88 FEP and 86 HC subjects. The excluded
individuals did not differ from the included ones with regard to
sex, age, years of education, BPRS total score, BPRS psychosis/
thought disturbance [62] and SANS total score. Sociodemographic
as well as clinical characteristics of the included individuals are
presented in Table 1. There were no sex differences in ARMS, FEP,
HC and in the total group with regard to age, years of education, use
of antipsychotics, BPRS total score and SANS total score except for
more pronounced psychosis/thought disturbance of women in the
total group (ARMS + FEP) and an older age of women in the HC
group.
3.2. Effects of sex and diagnostic group on cognitive functioning
Sex differences between men and women in the total group as
well as within each diagnostic group separately for each cognitive
performance measure are displayed in Fig. 1. Means and S.D. per
group are presented in Table 2. In the ANCOVA model used,
diagnostic group (ARMS, FEP, HC) and sex served as between
subject factors with age, years of education and use of anti-
psychotics being selected as covariates. There was one significant
interaction effect in verbal IQ (P = 0.028; Table 3), which was due to
a non-significantly worse performance of women in the ARMS
(d = "0.286) (Supplementary Table 2) and FEP group (d = "0.168)
(Supplementary Table 3) and a non-significantly better perfor-
mance in the HC group (d = 0.177) (Supplementary Table 4).
However, this interaction was no longer significant after correction
for multiple testing.
Effects of diagnostic group are presented in Table 3 and have
already been described previously [53]. We will not describe this
aspect any further because it is not the focal point of the present
study.
In the total group (ARMS + FEP + HC), women remembered
more words in the CVLT trials 1–5 (P = 0.046, d = 0.258; Table 3,
Supplementary Table 5) and showed less retroactive interference
(i.e., influence of newly learned words on the recall of previously
learned words, P = 0.048, d = 0.270; Table 3, Supplementary Table
5). By contrast, in the total group men demonstrated a shorter
working memory reaction time (P = 0.046, d = "0.236; Table 3,
Supplementary Table 5). However, all these significant sex
differences did not withstand correction for multiple testing.
Considering each group separately there were no sex differ-
ences in ARMS and FEP (Supplementary Tables 2 and 3). In the
group of HC, there was only one significant sex difference.
Specifically, men demonstrated less response bias in the Go/No-
Go task (P = 0.011, d = "0.352; Supplementary Table 4), but only if
uncorrected for multiple testing.
Sex-related cognitive performance differences were also
separately investigated in ARMS patients with and without later
transition to psychosis (ARMS-T vs. ARMS-NT). The results of the
ANCOVAs are reported in Supplementary Table 6 and Fig. 1, means
and S.D. are provided in Supplementary Table 7, and stratified
analyses are reported in Supplementary Tables 8 and 9.
4. Discussion
To the best of our knowledge, this is the first study investigating
sex-related neurocognitive performance differences in a sample of
HC, ARMS and FEP patients. In line with our hypothesis, we
found that women perform better in the domain of verbal learning
and memory independent of diagnostic group. Furthermore,
men as compared to women showed a shorter reaction time in
the working memory task. Additionally, we found a sex # group
interaction effect on verbal IQ, which was due to a non-
significantly worse performance of women in the ARMS and FEP
group and a non-significantly better performance in the HC group.
All these results, however, did not withstand correction for
multiple testing. Given that sex-related cognitive performance
differences have been found to be rather small [35], we decided to
discuss findings that were only significant at an uncorrected level
to account for potential false negative results.
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Table 1
Sample description.
Total group ARMS FEP HC
Men
(n=174)
Women
(n=118)
P-value N Men
(n=73)
Women
(n=45)
P-value Men (n=56) Women
(n=32)
P-value Men (n=45) Women
(n=41)
P-value
Age 26.2 (6.67) 27.7 (8.92) 0.133 292 25.6 (6.36) 27.2 (9.67) 0.326 29.2 (7.35) 30.3 (10.4) 0.579 23.6 (4.77) 26.2 (6.22) 0.038*
Years of education 11.7 (2.99) 12.1 (3.04) 0.316 292 11.8 (3.04) 11.8 (3.00) 0.997 11.3 (3.08) 11.4 (3.12) 0.826 12.3 (2.74) 13.0 (2.87) 0.244
Antipsychotics currentlya 0.989 290 0.150 0.770 1.000
No 148 (85.5%) 101 (86.3%) 70 (95.9%) 39 (88.6%) 33 (60.0%) 21 (65.6%) 45 (100%) 41 (100%)
Yes 25 (14.5%) 16 (13.7%) 3 (4.11%) 5 (11.4%) 22 (40.0%) 11 (34.4%) 0 (0.00%) 0 (0.00%)
Chlorpromazine equivalent
dose (mg)
221 (179) 204 (141) 0.735 40 217 (76.4) 245 (155) 0.742 222 (190) 185 (138) 0.538 – –
Antipsychotics compound 0.123 290 0.198 0.124 1.000
None 148 (85.5%) 101 (86.3%) 70 (95.9%) 39 (88.6%) 33 (60.0%) 21 (65.6%) 45 (100%) 41 (100%)
Aripiprazole 0 (0.00%) 2 (1.71%) 0 (0.00%) 0 (0.00%) 0 (0.00%) 2 (6.25%) 0 (0.00%) 0 (0.00%)
Risperidone 6 (3.47%) 8 (6.84%) 1 (1.37%) 3 (6.82%) 5 (9.09%) 5 (15.6%) 0 (0.00%) 0 (0.00%)
Quetiapine 6 (3.47%) 2 (1.71%) 0 (0.00%) 0 (0.00%) 6 (10.9%) 2 (6.25%) 0 (0.00%) 0 (0.00%)
Olanzapine 13 (7.51%) 4 (3.42%) 2 (2.74%) 2 (4.55%) 11 (20.0%) 2 (6.25%) 0 (0.00%) 0 (0.00%)
Antidepressants currently 0.692 290 0.854 0.694 1.000
No 139 (80.3%) 97 (82.9%) 49 (67.1%) 28 (63.6%) 45 (81.8%) 28 (87.5%) 45 (100%) 41 (100%)
Yes 34 (19.7%) 20 (17.1%) 24 (32.9%) 16 (36.4%) 10 (18.2%) 4 (12.5%) 0 (0.00%) 0 (0.00%)
Tranquilizer currently 0.525 290 0.242 0.835 1.000
No 148 (85.5%) 96 (82.1%) 61 (83.6%) 32 (72.7%) 42 (76.4%) 23 (71.9%) 45 (100%) 41 (100%)
Yes 25 (14.5%) 21 (17.9%) 12 (16.4%) 12 (27.3%) 13 (23.6%) 9 (28.1%) 0 (0.00%) 0 (0.00%)
BPRS total score 43.2 (11.7) 45.7 (12.7) 0.191 175 38.7 (9.57) 41.0 (10.7) 0.265 50.0 (11.4) 52.2 (12.6) 0.449 – –
BPRS psychosis/thought disturbance 7.85 (3.64) 9.10 (4.21) 0.045* 178 5.92 (2.29) 6.93 (3.02) 0.072 10.8 (3.33) 12.3 (3.67) 0.093 – –
SANS total score 24.8 (16.3) 21.2 (15.7) 0.166 155 25.3 (17.6) 18.9 (16.3) 0.084 24.2 (14.8) 24.2 (14.7) 0.992 – –
ARMS: at-risk mental state; FEP: first episode psychosis; HC: healthy controls; BPRS: Brief Psychiatric Rating Scale; SANS: Scale for the Assessment of Negative Symptoms. Regarding psychopathological measures (BPRS and SANS),
the total group consists of ARMS+FEP (without the HC’s); mean and standard deviation of chlorpromazine equivalent doses are shown for those patients on antipsychotics (not for the overall group); continuous variables are
described by means and standard deviation in brackets.
a Three ARMS patients out of 110 (two men and one woman) and three FEP patients out of 55 not taking antipsychotics (two men and one woman) were antipsychotic free and not naive.
* P<0.05.
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Our finding that women perform better in the domain of verbal
learning and memory across all diagnostic groups is consistent
with a large body of evidence [11,25,36,45,67]. Since we did not
find an interaction between diagnostic group and verbal learning
and memory, our results suggest that the sex advantage of women
in verbal learning and memory is equally present in ARMS as in FEP
and HC individuals [49]. As previous studies did not compare ARMS
with HC and FEP individuals, this has not been demonstrated
previously. Unexpectedly, we found that men had a shorter
reaction time in the 2-back task than women independent of
diagnostic group. This could indicate that men have a superior
working memory performance since they responded faster during
the target trials, while maintaining a comparable overall perfor-
mance level. This result cannot be better explained by a generally
enhanced processing speed as no sex differences in reaction time
during CPT and Go/No-Go were detected. Our finding of a
significant sex ! group interaction in verbal IQ is difficult to
explain as it is not substantiated by the literature. One potential
explanation for a worse performance of women in the ARMS and
FEP group could be that women in our sample have more severe
positive symptoms than men as indicated by the BPRS psychosis/
thought disturbance dimension score. However, an association
between positive symptoms and verbal IQ has not been established
in the literature and only appears to exist for negative and
disorganised symptom dimensions [2,6].
Some earlier studies [21,48], which did not detect any sex
differences in cognitive functioning were conducted in chronic
schizophrenia patients who were seriously impaired and therefore
represented a different patient population. It is conceivable that
sex differences at a very low level of functioning do not exist or that
they could not be detected because of floor effects. In the present
study, we included mainly antipsychotic naı¨ve ARMS and FEP
Fig. 1. Cognitive performance of women compared to men in at-risk mental state (ARMS) for psychosis individuals, first episode psychosis (FEP) patients, healthy controls
(HC) and in the total group. The dotted horizontal line at zero represents the performance of men. Differences are expressed in units of Cohen’s d and are significant if the 95%
confidence interval (vertical line) does not overlap with zero. Variables with a minus sign were reversed so that positive scores always represent good performance.
Differences are adjusted for the influence of age, years of education and use of antipsychotics. In the total group, we additionally corrected for diagnostic group. ARMS: at-risk
mental state; FEP: first episode psychosis; HC: healthy controls; total: ARMS + FEP + HC; ToH: Tower of Hanoi; WCS: Wisconsin Card Sorting Test; CPT: Continuous
Performance Task; CVLT: California Verbal Learning Task.
S. Ittig et al. / European Psychiatry 30 (2015) 242–250246
30
Table 2
Means and standard deviations of neuropsychological test data in ARMS, FEP, and HC.
Total group ARMS FEP HC
[ALL]
(n=292)
Men
(n=174)
Women
(n=118)
[ALL]
(n=118)
Men
(n=73)
Women
(n=45)
[ALL]
(n=88)
Men
(n=56)
Women
(n=32)
[ALL]
(n=86)
Men
(n=45)
Women
(n=41)
Non-verbal IQ 28.0 (5.67) 27.8 (5.63) 28.3 (5.74) 28.0 (5.38) 28.5 (5.64) 27.1 (4.82) 25.4 (5.97) 25.2 (5.54) 25.8 (6.73) 30.8 (4.37) 29.9 (4.43) 31.6 (4.18)
Verbal IQ 29.0 (4.13) 29.1 (4.19) 29.0 (4.08) 28.9 (4.01) 29.4 (3.80) 28.1 (4.25) 27.9 (4.81) 28.0 (5.07) 27.6 (4.44) 30.4 (3.10) 29.8 (3.45) 31.1 (2.58)
ToH total time 563 (385) 548 (355) 588 (433) 532 (329) 517 (305) 564 (377) 739 (513) 704 (474) 807 (583) 443 (236) 426 (175) 464 (293)
ToH 4 and 5 disc moves 83.3 (35.5) 85.5 (36.5) 79.8 (33.8) 82.3 (36.1) 83.2 (38.2) 80.6 (31.8) 95.1 (36.5) 101 (39.1) 83.1 (27.9) 74.0 (31.0) 71.5 (21.7) 76.8 (39.2)
WCS total assignments 82.0 (10.6) 82.6 (10.6) 81.0 (10.5) 82.5 (10.5) 82.9 (10.8) 81.6 (9.99) 85.9 (9.89) 85.9 (10.1) 85.9 (9.77) 77.5 (9.74) 78.2 (9.55) 76.7 (10.0)
WCS preservation score 21.3 (17.4) 22.5 (17.7) 19.5 (16.8) 21.4 (17.1) 23.2 (17.8) 18.2 (15.4) 26.6 (18.0) 27.6 (18.1) 24.9 (17.9) 16.1 (15.7) 15.6 (15.1) 16.6 (16.6)
Go/No-Go reaction time 544 (96.3) 543 (91.3) 545 (103) 557 (107) 550 (95.5) 569 (122) 563 (88.0) 566 (87.7) 558 (89.8) 507 (78.4) 506 (78.1) 508 (79.6)
Go/No-Go c (response bias) 0.05 (0.22) 0.04 (0.24) 0.05 (0.19) 0.04 (0.19) 0.04 (0.17) 0.04 (0.22) 0.09 (0.32) 0.10 (0.36) 0.07 (0.24) 0.02 (0.11) !0.01 (0.13) 0.04 (0.08)
Go/No-Go d0 (sensitivity) 3.94 (0.63) 3.94 (0.60) 3.94 (0.67) 3.97 (0.59) 4.04 (0.42) 3.87 (0.79) 3.72 (0.84) 3.69 (0.88) 3.78 (0.79) 4.11 (0.28) 4.07 (0.30) 4.15 (0.26)
WM reaction time 651 (215) 637 (217) 671 (211) 691 (233) 659 (240) 743 (212) 688 (220) 683 (220) 698 (222) 559 (149) 547 (138) 571 (161)
WM c (response bias) 0.48 (0.33) 0.50 (0.36) 0.46 (0.30) 0.56 (0.31) 0.58 (0.32) 0.52 (0.30) 0.45 (0.41) 0.46 (0.44) 0.42 (0.34) 0.42 (0.25) 0.40 (0.25) 0.43 (0.25)
WM d0 (sensitivity) 3.02 (0.90) 3.05 (0.90) 2.97 (0.91) 2.96 (0.88) 3.00 (0.88) 2.91 (0.88) 2.72 (1.00) 2.76 (1.00) 2.64 (1.01) 3.38 (0.71) 3.46 (0.62) 3.28 (0.79)
CPT reaction time 439 (124) 433 (121) 449 (129) 454 (134) 432 (117) 490 (153) 470 (133) 463 (137) 482 (127) 392 (82.1) 399 (95.5) 384 (64.4)
CPT slowing 1.04 (0.13) 1.04 (0.13) 1.05 (0.13) 1.04 (0.11) 1.03 (0.11) 1.05 (0.12) 1.07 (0.16) 1.05 (0.17) 1.09 (0.15) 1.02 (0.10) 1.03 (0.11) 1.02 (0.10)
CPT c (response bias) 0.12 (0.20) 0.11 (0.17) 0.13 (0.24) 0.09 (0.19) 0.10 (0.16) 0.06 (0.22) 0.18 (0.23) 0.15 (0.18) 0.24 (0.30) 0.10 (0.17) 0.08 (0.16) 0.12 (0.17)
CPT d0 (sensitivity) 4.99 (0.54) 4.99 (0.54) 4.97 (0.54) 4.96 (0.53) 5.01 (0.48) 4.89 (0.60) 4.85 (0.64) 4.88 (0.67) 4.80 (0.59) 5.14 (0.41) 5.10 (0.44) 5.18 (0.36)
CVLT total correct trial 1–5 59.1 (9.90) 57.9 (10.0) 60.9 (9.52) 59.4 (9.76) 58.6 (9.70) 60.9 (9.84) 55.8 (10.5) 54.8 (10.5) 57.4 (10.5) 63.6 (7.03) 62.0 (8.21) 65.4 (4.99)
CVLT long delay free recall 13.4 (2.53) 13.1 (2.69) 13.8 (2.24) 13.9 (1.95) 13.8 (1.99) 13.9 (1.90) 12.3 (3.10) 11.9 (3.35) 12.8 (2.69) 14.2 (1.84) 13.6 (2.11) 14.8 (1.30)
CVLT semantic cluster ratio 1.79 (0.90) 1.73 (0.86) 1.90 (0.95) 1.78 (0.94) 1.79 (0.92) 1.78 (0.99) 1.64 (0.74) 1.57 (0.72) 1.76 (0.78) 2.06 (1.01) 1.87 (0.96) 2.27 (1.04)
CVLT serial cluster ratio 0.12 (0.11) 0.13 (0.12) 0.12 (0.10) 0.13 (0.12) 0.13 (0.13) 0.13 (0.11) 0.11 (0.08) 0.11 (0.08) 0.10 (0.07) 0.12 (0.15) 0.13 (0.16) 0.11 (0.14)
CVLT percent primacy recall 27.6 (3.86) 27.7 (3.81) 27.6 (3.97) 27.4 (3.81) 27.4 (3.30) 27.5 (4.65) 28.4 (4.60) 28.5 (4.90) 28.3 (4.17) 26.8 (2.16) 26.9 (2.21) 26.7 (2.16)
CVLT percent middle recall 46.8 (4.17) 46.8 (4.56) 47.0 (3.51) 47.1 (4.22) 47.2 (4.37) 46.9 (3.99) 46.0 (4.71) 45.7 (5.38) 46.6 (3.41) 47.6 (2.84) 47.7 (2.83) 47.5 (2.91)
CVLT percent recency recall 25.5 (3.47) 25.6 (3.57) 25.4 (3.34) 25.5 (3.72) 25.4 (3.88) 25.6 (3.47) 25.5 (3.74) 25.8 (3.75) 25.1 (3.74) 25.6 (2.42) 25.4 (2.30) 25.8 (2.59)
CVLT proactive interference 0.97 (2.39) 0.95 (2.43) 0.99 (2.34) 0.87 (2.58) 0.95 (2.67) 0.72 (2.45) 1.44 (2.09) 1.36 (1.97) 1.57 (2.30) 0.40 (2.34) 0.21 (2.50) 0.62 (2.18)
CVLT retroactive interference 0.98 (1.67) 1.17 (1.69) 0.68 (1.60) 0.99 (1.58) 1.03 (1.56) 0.91 (1.65) 1.10 (1.89) 1.36 (1.93) 0.68 (1.76) 0.76 (1.46) 1.12 (1.57) 0.33 (1.24)
Total score 0.00 (1.00) !0.06 (0.98) 0.08 (1.02) !0.01 (0.85) 0.04 (0.82) !0.10 (0.90) !0.65 (1.05) !0.71 (1.03) !0.54 (1.10) 0.68 (0.62) 0.60 (0.59) 0.77 (0.64)
ARMS: at-risk mental state; FEP: first episode psychosis; HC: healthy controls; ToH: Tower of Hanoi; WCS:Wisconsin Card Sorting Test;WM:workingmemory; CPT: Continuous Performance Task; CVLT: California Verbal Learning
Task.
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individuals and therefore it should be noticed that our sample is
not comparable to chronic schizophrenia patients. There are four
studies, which included a FEP or first episode schizophrenia sample
in their analysis of sex dependant cognitive performance
differences. Ayesa-Arriola et al. [5] included 160 FEP and
159 HC in their study. Women outperformed men (FEP + HC) in
a task of verbal memory (Rey auditory verbal learning test: trials
1–5) whereas men outperformed women on measures of reaction
time (CPT reaction time), visual memory (Corsi blocks backward,
Rey figure recall) and executive functions (Tower of London: total
move score). Hoff et al. [32] could show a better performance for
women in verbal learning and memory (CVLT) and a better
performance of men in executive functioning measured by the
WCST. Albus et al. [3] found a difference between the sexes (first
episode schizophrenia patients and HC) in verbal learning and
memory (CVLT) showing a better performance of women. The
study of Zhang et al. [72] depicted no sex differences in
neuropsychological task performance in first episode schizophre-
nia patients but they did not measure verbal learning and memory.
To sum up: 3 out of 4 studies described better performance of
women in verbal learning and memory and 2 out of 4 studies
described an advantage of men in executive functioning. The better
functioning in verbal learning and memory is in line with our
findings whereas the finding of better performance of men in
executive functioning was not supported by our data.
The following limitations should be taken into account: Our
neuropsychological tasks were originally selected to assess the
risk of psychosis and not specifically to detect sex differences.
Therefore, our test battery did not include some of the most
sensitive tasks to detect sex differences such as visuo-spatial or
mental rotation tasks. Furthermore, meta-analyses suggest that
sex-related cognitive performance differences are rather small
[35]. Hence, our modest sample size could have precluded the
detection of some sex effects. Another important aspect to consider
is the conceptual difference of gender and sex. While gender refers
to masculinity/femininity rooted in sociocultural descriptions
(measured by a questionnaire), sex is a biologically reduced and
dichotomous term. Results of Lewine et al. [43] indicate stronger
gender than sex effects. Accordingly, in this paper we used the
term sex because we did not evaluate gender. Finally, it should be
noted that neuropsychological performance in women has been
shown to fluctuate with their monthly cycle [17,29,33,39], which
we did not control in this study. High levels of ovarian hormones in
the midluteal phase may facilitate certain skills that show a female
advantage, while being detrimental to skills that normally show a
male advantage [39]. Thus, it is possible that some effects would
have been more pronounced if we had measured women at a
specific point during their monthly cycle.
Taken together, our results suggest that sex differences in
cognitive functioning in ARMS and FEP patients are not different
from those seen in HC. Specifically, the female advantage in verbal
learning and memory, which has frequently been found in HC
seems equally present in ARMS and FEP patients. Future studies
should also consider menstrual status in women as well as making
a distinction between gender and sex to identify potential
differences in cognitive functioning.
Table 3
P-values of ANCOVAs with ARMS, FEP and HC.
Uncorrected Corrected
Group Sex Group ! sex Group Sex Group ! sex
IQ
Non-verbal IQ <0.001*** 0.516 0.797 0.002** 0.777 0.945
Verbal IQ 0.014 0.308 0.028* 0.033* 0.665 0.739
Executive functions
ToH total time 0.006** 0.192 0.650 0.016* 0.665 0.945
ToH 4 and 5 disc moves 0.015* 0.344 0.916 0.034* 0.665 0.945
WCS total assignments 0.002** 0.496 0.921 0.011* 0.777 0.945
WCS preservation score 0.059 0.272 0.558 0.101 0.665 0.945
Go/No-Go reaction time 0.003** 0.530 0.634 0.013 0.777 0.945
Go/No-Go c (response bias) 0.238 0.580 0.505 0.310 0.777 0.945
Go/No-Go d0 (sensitivity) 0.170 0.877 0.763 0.237 0.908 0.945
Attention and working memory
WM reaction time <0.001*** 0.046* 0.639 <0.001*** 0.413 0.945
WM c (response bias) 0.005** 0.358 0.103 0.015* 0.665 0.945
WM d0 (sensitivity) 0.001** 0.239 0.290 0.008** 0.665 0.945
CPT reaction time 0.004** 0.212 0.821 0.013* 0.665 0.945
CPT slowing 0.173 0.141 0.913 0.237 0.665 0.945
CPT c (response bias) 0.061 0.627 0.334 0.101 0.777 0.945
CPT d0 (sensitivity) 0.019* 0.326 0.410 0.038* 0.665 0.945
Verbal learning and memory
CVLT total correct trial 1–5 0.012* 0.046* 0.938 0.031* 0.413 0.945
CVLT long delay free recall 0.062 0.098 0.859 0.101 0.634 0.945
CVLT semantic cluster ratio 0.267 0.241 0.624 0.316 0.665 0.945
CVLT serial cluster ratio 0.324 0.522 0.279 0.367 0.777 0.945
CVLT percent primacy recall 0.746 0.636 0.660 0.775 0.777 0.945
CVLT percent middle recall 0.256 0.716 0.767 0.316 0.810 0.945
CVLT percent recency recall 0.579 0.908 0.945 0.627 0.908 0.945
CVLT proactive interference 0.101 0.870 0.890 0.155 0.908 0.945
CVLT retroactive interference 0.920 0.048* 0.362 0.920 0.413 0.945
Composite
Total score <0.001*** 0.658 0.886 <0.001*** 0.777 0.945
ARMS: at-risk mental state; FEP: first episode psychosis; HC: healthy controls; ToH: Tower of Hanoi; WCS: Wisconsin Card Sorting Test; WM: working memory; CPT:
Continuous Performance Task; CVLT: California Verbal Learning Task.
* P < 0.05.
** P < 0.01.
*** P < 0.001.
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Abstract
Aim: Research findings on the corre-
lations between self-rating and
observer-rating of schizophrenic psy-
chopathology are inconsistent and
have rarely considered first-episode
psychosis (FEP) and at-risk mental
state (ARMS) for psychosis patients.
This study investigates these correla-
tions in ARMS and FEP patients and
how they are moderated by disease
stage and gender.
Methods: In the Basel Früherkennung
von Psychosen (FePsy) study, positive
and negative psychotic and affective
symptoms were rated in 126 ARMS
and 94 FEP patients using two
observer- and three self-rating scales.
The agreement between self-rating
and observer-rating and themoderat-
ing influence of disease stage and
gender was quantified using Pearson
correlation and multiple regression
models.
Results: Correlations between self-
and observer-rated subscales
covering the same symptom dimen-
sion were low and mostly non-
significant except for one correlation
of positive and one of negative symp-
toms. There was no moderating influ-
ence of disease stage and gender on
the correlations between self-rating
and observer-rating except for one
higher association in positive symp-
toms in FEP compared to ARMS and
in women compared to men.
However, these significant interaction
effects did not withstand correction
for multiple testing.
Conclusions: This study suggests that
the agreement between self-rating
and observer-rating in FEP and ARMS
patients is rather low, similar across
symptom dimensions, and only par-
tially dependent on disease stage and
gender. However, low correlations
between self-rating and observer-
rating do not necessarily indicate that
these patients have difficulties report-
ing their symptoms. They could also
have occurred because the scales did
not exactly cover the same symptom
dimensions.
Key words: gender, observer-rating, psychosis, self-rating.
INTRODUCTION
The coherence between self-rating and observer-
rating in the assessment of psychopathology of
schizophrenic psychoses is an emerging topic in
current research.1–4 Observer-rating scales are
widely used1,4,5 and considered objective measures
of the severity of psychopathological symptoms in
patients with a psychotic disorder,6 but they need a
well-trained professional and are time-
consuming.1,3 Self-rating scales, on the other hand,
are more easily applicable. However, it is unclear
whether self- and observer-rating scales measure
similar constructs and whether psychosis patients
are able to report their symptoms with sufficient
accuracy.7
As schizophrenia patients have many features
(e.g. poor insight, denial, delusions, cognitive
Early Intervention in Psychiatry 2015; ••: ••–•• doi:10.1111/eip.12270
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deficits) that could hinder an accurate self-rating of
their symptoms, it has long been assumed that self-
ratings – especially of positive psychotic symptoms
– are unreliable in these patients.8,9 However, our
literature research revealed that at least six studies
found a good agreement between self-rating and
observer-rating of positive psychotic symptoms in
psychosis patients3,4,9–12 and only three studies
found poor correlations.13–15
With respect to negative symptoms, the concord-
ance between self- and observer-rating scales seems
to be rather inconsistent. Some studies found nega-
tive symptoms more difficult to be accurately
reported than positive symptoms,3,9,10 whereas other
studies suggested that even patients with a schizo-
phrenic, schizoaffective or acute psychotic disorder
are able to accurately report them.11,12 A further
study by Bottlender et al.16 found equivocal results
as it showed good agreement in the SANS (Scale for
the Assessment of Negative Symptoms) total
score but not in the subscales Apathy, Alogia and
Attention.
Studies assessing the concordance between self-
rating and observer-rating of depressive symptoma-
tology in psychosis patients mostly showed good
agreements.13,15,17 A recent study identified 49.2% of
the patients to have equal self-rating and observer-
rating in depressive symptoms.1 However, Lasalvia
et al.14 found significant correlations between affec-
tive symptoms only in non-psychosis but not in psy-
chosis patients.
One explanation for these inconsistent results is
that inmany studies self- and observer-rating scales
did not tap exactly the same symptom dimension.
Additionally, existing studies vary in several factors
that can potentially moderate the relationship
between self-rating and observer-rating, such as
disease state, diagnostic group, degree of insight
and gender distribution. However, only few studies
have investigated the influence of these moderating
factors. Below, we will summarize the literature
regarding the influence of disease stage and gender,
as our study will focus specifically on these factors.
To our knowledge, no study has investigated
whether the agreement between self-rating and
observer-rating differs between patients with a first-
episode psychosis (FEP) and those who have an
at-risk mental state (ARMS) for psychosis. Existing
studies have only focused on one of these disease
stages. FEP patients were found to have a good asso-
ciation in positive but not in negative symptoms,10
whereas ARMS patients were shown to have more
psychosis risk symptoms in self-reports than in
clinical interviews.18 However, as lack of insight can
lead to a decreased agreement between self-rating
and observer-rating4 and as FEP patients were
found to have more impaired insight than ARMS
patients,19 it is reasonable to assume that a direct
comparison between ARMS and FEP patients would
show a higher agreement in ARMS patients.
Although gender differences in schizophrenia
have been described in almost all aspects, including
age of onset, incidence, symptomatology, treatment
response and outcome,20–22 little is known about
whether gender influences the agreement between
self-rating and observer-rating. Some studies
showed a higher agreement of affective symptoms
in women compared to men in mixed patient
samples or patients with depression.23,24 However,
other studies do not support these findings in
samples with psychotic and non-psychotic major
depression.17,25 To our knowledge, only one study
investigated the influence of gender on the agree-
ment between self-rating and observer-rating of
positive psychotic symptoms in schizophrenia
patients.4 This study found no influence of gender.
To improve on previous studies, this study aimed
to compare self-rating and observer-rating of affec-
tive, negative and positive symptoms in both ARMS
and FEP patients. Furthermore, we aimed to inves-
tigate whether the agreement was dependent on
disease stage and gender. We hypothesized that the
association between self-rating and observer-rating
is higher in ARMS than in FEP patients and higher in
women than in men.
METHODS
Setting and recruitment
All data were collected as part of the Basel
Früherkennung von Psychosen (FePsy) project, a
prospectivemultilevel study, which aims to improve
the early detection of psychosis.26,27 The study was
approved by the ethics committee of the University
of Basel, and all participants provided written
informed consent. Patients were recruited from 1
March 2000 to 31 January 2013 via the FePsy Clinic,
which was specifically set up to identify, assess and
treat individuals in the early stages of psychosis.
Screening procedure
Screening of ARMS and FEP patients was performed
with the Basel Screening Instrument for Psychosis
(BSIP), which has been shown to have a good
interrater reliability (K = 0.67) and a high predictive
validity.28 Individuals were classified by the BSIP as
being in an ARMS for psychosis, having a FEP, or
Rater agreement in emerging psychosis
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being not at risk for psychosis using criteria corre-
sponding to those of Yung et al.29
Assessment of psychopathology
The Brief Psychiatric Rating Scale ExpandedVersion
(BPRS-E)30 and the SANS31 were used as observer-
ratings and the Frankfurt Complaint Questionnaire
(FCQ),32 the Selfscreen-Prodrome (SSP)33 and the
Paranoid Scale (PS)34 were used as self-ratings of
psychopathological symptoms.
The BPRS-E is a widely used rating scale for
assessing general psychopathology and consists of
24 items, which can be grouped to the four
subscales Depression/Anxiety, Psychosis, Negative
Symptoms and Activation.35 All BPRS-E items are
rated on a 7-point severity scale.
The SANS is a 24-item scale for assessing negative
symptoms. The items of the SANS are rated on a
5-point ordinal scale and are grouped to five
subscales: Affective Flattening, Alogia, Apathy/
Avolition, Anhedonia/Asociality and Attention.
The FCQ contains 98 dichotomous items and is
used to assess so-called ‘basic symptoms’, which are
abnormal subjective experiences that can occur in a
prodromal state of psychosis and that seem tohave a
predictive validity for the onset of psychosis.36 These
symptoms have been called ‘basic’ to indicate their
proximity tohypothesizedbasic neural dysfunctions
of schizophrenia.37 The FCQ contains four factors:
Depression, Disturbances of automated responses,
Perceptual disturbances and Overinclusion.32
The PS consists of a subset of items of the Paranoid
Depression Scale that contains paranoid and depres-
sive symptoms.The PS comprises 14 itemswhich can
begrouped into the threesubscalesParanoidTenden-
cies, Test Motivation and Denial of Illness.
The SSP is a screening instrument to identify
patients with a risk for psychosis. It consists of 32
dichotomous items regarding prodromal and
prepsychotic symptomatology.
All observer measures were conducted by well-
trained psychologists or psychiatrists.
Statistical analysis
Analyses were performed using the Statistical
Package for the Social Sciences (SPSS) forWindows,
version 19, and the R environment for statistical
computing.38 Differences in sociodemographic and
clinical characteristics between ARMS and FEP
patients were tested with t and χ2 tests.
First we used Pearson correlations to compare the
already existing and published subscales of the five
self- and observer-rating instruments. However,
because these rating scales frequently differ in their
item content, we also constructed new subscales
fromself-rating items thatwereas similar aspossible
to the original scales in the BPRS and SANS. Specifi-
cally, by applying hierarchical item cluster analysis39
and based on theoretical knowledge about the
dimensional structure of psychopathology, we
grouped the items of each self-rating scale to the
subscales Affective Symptoms, Positive Symptoms
andNegative Symptoms in suchaway that theywere
most similar to BPRSDepression/Anxiety, BPRS Psy-
chosis and SANS total score, respectively. For assess-
ingnegative symptoms,weused theSANS total score
instead of the BPRS subscale for negative symptoms
because it covers this symptom dimension more
completely and reliably. With the PS items, only the
newsubscale (‘Positive Symptoms’)was formed.The
items of each newly formed subscale are shown in
Supplementary Table S1. To evaluate the internal
consistency and homogeneity of the new subscales,
Cronbach’s α40 and Revelle’s β39 were calculated. In
case of dichotomous and polytomous items, these
measures were based on tetrachoric and polychoric
correlations, respectively.
To evaluate the correlations between all self- and
observer-rated scales we generated a Multitrait-
multimethod matrix. This approach evaluates the
construct validity of measures of different concepts
assessed by different methods.41 It shows how the
correlations between different measures vary as a
function of different item content and method.
Although all psychopathological assessments
were obtained at baseline, they were not always
obtained at the same visit. Hence, in accordance
with previous studies,10,16 we correlated only those
measures of each patient that were obtained within
a period of 7 days.
To examine whether gender and disease stage
moderate the correlations between self-rating and
observer-rating,multiple regressionmodelswith the
observer-rating scale asdependent variable, the self-
rating scale as the first independent variable and
disease stage or gender as the second independent
variables, and the interactions between these vari-
ables were performed. To facilitate interpretation,
continuous variables were z-transformed.
To correct for multiple testing, P-values were
adjusted using the Benjamini–Hochberg method.42
RESULTS
Sample description
Sociodemographic sample characteristics are
presented in Table 1. ARMS did only differ from
A. Spitz et al.
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FEP patients regarding age (t(185) = −3.69,
P < .001).
Clinical characteristics of our sample are shown
in Table 2. FEP patients had higher scores in all
scales assessing positive and basic symptoms.
However, they did not differ in negative symptoms
scales except for a higher score of FEP patients in the
newly constructed self-rating SSP Negative
Symptom scale. With regard to affective symptoms,
FEP scored higher in the BPRS Depression/Anxiety
and self-rating FCQ Affective Symptoms scales, but
not in the self-rating SSP Affective Symptoms scale.
Associations between self-rating and
observer-rating
Correlations of the original subscales between self-
rating and observer-rating are illustrated in
Figure 1. The highest correlations between
subscales with similar item content were between
TABLE 1. Sociodemographic sample characteristics
Total ARMS (n = 126) FEP (n = 94) P-value
Gender 0.649
Female 81 48 33
Male 139 78 61
Age mean (SD) 27.4 25.7 (7.5) 29.8 (8.6) <0.001***
Years of education mean (SD) 11.4 (3.0) 11.7 (3.1) 11.1 (3.0) 0.109
*P < 0.05; **P < 0.01; ***P < 0.001.t-tests for independent samples were used for continuous variables, χ2 tests for categorical variables. ARMS, at-risk
mental state; FEP, first-episode psychosis.
TABLE 2. Clinical sample characteristics
Total ARMS (n = 126) FEP (n = 94) P-value N
ARMS/FEP
BPRS Depression/Anxiety 9.86 (3.85) 9.23 (3.5) 10.66 (4.08) 0.008** 113/89
BPRS Psychosis/Thought Disturbance 8.61 (3.768) 6.44 (2.2) 11.38 (3.56) <0.001*** 114/89
BPRS Negative Symptoms 6.08 (2.87) 6.16 (2.93) 5.99 (2.79) 0.676 113/89
BPRS Activation 6.21 (2.65) 5.45 (1.89) 7.18 (3.14) 0.000*** 113/89
BPRS Total score 45.64 (12.47) 40.4 (9.35) 52.29 (12.8) <0.000*** 113/89
SANS Affective Flattening 5.75 (6.42) 5.81 (6.40 5.67 (6.47) 0.878 112/85
SANS Alogia 3.39 (3.98) 3.27 (3.89) 3.55 (4.13) 0.624 113/84
SANS Avolition-Apathy 5.81 (3.28) 5.55 (2.98) 6.16 (3.62 0.206 114/85
SANS Asociality-Anhedonia 7.7 (5.23) 7.7 (5.18) 7.77 (5.32) 0.923 110/84
SANS Inattention 1.87 (2.01) 1.59 (1.59) 2.22 (2.42) 0.049* 100/78
SANS Total score 24.37 (16.76) 23.77 (16.28) 25.18 (17.44) 0.560 114/85
FCQ Disturbances of automated responses 6.74 (5.68) 5.51 (4.64) 8.38 (6.51) 0.005** 77/58
FCQ Perceptual disturbances 4.97 (5.22) 3.41 (3.03) 7.07 (6.65) <0.001*** 78/58
FCQ Depression 9.10 (6.52) 7.59 (5.82) 11.12 (6.90) 0.002** 78/58
FCQ Overinclusion 7.13 (4.65) 6.21 (4.00) 8.36 (5.17) 0.01* 77/58
FCQ Total score 28.32 (19.97) 23.14 (15.39) 35.19 (23.19) 0.001** 77/58
SSP Total 15.61 (9.89) 15.33 (6.71) 16.05 (7.23) 0.611 63/39
PS Paranoid Tendencies 7.58 (7.50) 4.79 (4.60) 11.21 (8.91) <0.001*** 73/56
Adapted subscales
FCQ Affective Symptoms 3.41 (2.44) 2.94 (2.28) 4.05 (2.54) 0.008** 78/58
FCQ Positive Symptoms 6.88 (5.67) 5.29 (3.79) 9.02 (6.98) <0.001** 78/58
FCQ Negative Symptoms 9.44 (8.00) 7.46 (6.28) 12.10 (9.27) 0.001** 78/58
SSP Affective Symptoms 3.98 (1.88) 4.08 (1.86) 3.82 (1.93) 0.503 65/93
SSP Positive Symptoms 2.44 (2.02) 2.12 (1.88) 2.97 (2.15) 0.037* 65/93
SSP Negative Symptoms 4.38 (2.47) 4.60 (1.86) 3.82 (1.93) 0.023* 65/93
PS Positive Symptoms 7.16 (7.32) 4.35 (4.42) 10.79 (8.65) <0.001*** 75/58
*P < 0.05; **P < 0.01; ***P < 0.001.
Scale scores are presented as means with standard deviations in parentheses. t-tests for independent samples were used for continuous variables, χ2 tests
for categorical variables.
ARMS, at-risk mental state; BPRS, Brief Psychiatric Rating Scale; FCQ, Frankfurt Complaint Questionnaire; FEP, first-episode psychosis; PS, Paranoid Scale;
SANS, Scale for the Assessment of Negative Symptoms; SSP, Selfscreen-Prodrome.
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FCQ Perceptual disturbances and BPRS Psychosis
(r(63) = .342, P adjusted = .056) as well as between
PS Paranoid Tendencies and BPRS Psychosis
(r(70) = .455, P adjusted = .002).
Correlationsbetween the self-ratingandobserver-
rating, internal consistencies, homogeneities and
sample sizes of the newly constructed subscales are
illustrated in Table 3. The newly constructed
subscales showed a good internal consistency
(α = .86–.96)andhomogeneity (β = .7–.85).However,
internal consistencies of the BPRS Psychosis and
Depression/Anxiety subscaleswereα < .8 andα < .7,
respectively. Heterotrait–monomethod correlations
were higher than monotrait–heteromethod correla-
tions suggesting that there was more common vari-
ancedue to themethod than the content.Therewere
only two significant correlations between self- and
observer-rating scales covering the same symptom
dimension. Specifically, the FCQ Negative Symp-
toms subscale correlated significantlywith the SANS
scale (r(66) = .317, P adjusted = .021) and the PS
Positive Symptoms correlated significantly with the
BPRS Positive Symptoms subscale (r(70) = .454, P
adjusted < .001).
Influence of disease stage and gender on the
association between self-rating and
observer-rating
As shown in Figure 2, there were no Group × Self-
rating scale interactions in affective and negative
symptomatology. However, in positive symptoms,
there was one significant Disease stage × Self-rating
scale interaction with the FCQ Positive Symptom
scale, R2 = .534, F(1,63) = 7.38, P = .009, η2 = .108,
which was due to a higher correlation between self-
rating and observer-rating in FEP than in ARMS
patients. However, when corrected for multiple
testing, this interaction effect was only significant at
a trend level (P adjusted = .060).
In the analyses including gender, there was only
one statistically significant Gender × Self-rating
scale interaction, namely, with the SSP Positive
Symptoms subscale, R2 = .168, F(1,53) = 6.009,
P = .018, η2 = .105, suggesting that women showed a
higher correlation of this subscale with the BPRS
Positive Symptom scale than men (Fig. 3). However,
this significant interaction effect did not withstand
correction for multiple testing (P adjusted = .124).
DISCUSSION
The aim of this study was to investigate the correla-
tions of self-rating and observer-rating in ARMS and
FEP patients and the influence of disease stage and
gender on these correlations. Using the original
subscales, we found relatively high correlations in
positive symptom dimensions but not in the other
symptom dimensions. When the scales were
adapted to have better matching item contents,
we found two significant correlations between
FIGURE 1. Correlations of original self- and observer-rating subscales. *P < 0.05, **P < 0.01, ***P < 0.01, adjusted for multiple testing
by the Benjamini–Hochberg method. BPRS, Brief Psychiatric Rating Scale; FCQ, Frankfurt Complaint Questionnaire; PS, Paranoid Scale;
SANS, Scale for the Assessment of Negative Symptoms; SSP, Selfscreen-Prodrome.
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self-rating and observer-rating covering the same
symptom dimension, namely, one with positive and
one with negative symptoms. Furthermore, disease
stage and gender each moderated one pair of self/
observer-ratings, but only if P-values were uncor-
rected for multiple testing.
The construction of new subscales with more
homogeneous and better matching item content
improved the interpretability of the results and led
to higher self/observer agreements, particularly in
the domain of negative symptoms. However, overall
the correlations were still relatively small. Although
all seven pairs of subscales covering the same
symptom dimension correlated positively, only two
were statistically significant, indicating that the
agreements between self-rating and observer-rating
were rather low. Furthermore, no clear pattern
emerged with regard to strength of association and
symptom dimension. As we found statistically sig-
nificant correlationswith both positive and negative
symptoms, our results do not confirm earlier find-
ings of Hamera et al.9 and Preston and Harrison,10
according to whom negative symptoms are more
difficult to be accurately reported than positive
symptoms, but support earlier findings of Bell
et al.12 and Liraud et al.11 The lack of association
between scales measuring affective symptoms
stands in contrast to previous studies which
reported good agreements in this dimension.1,15
With regard to the moderating influence of the
disease stage, we could not confirm that the asso-
ciation between self-rating and observer-rating is
higher in ARMS than in FEP patients. However,
when P-values were not corrected for multiple
testing, there was one significant interaction which
was in the opposite direction of what we had
expected. Specifically, FEP showed higher correla-
tions than ARMS patients between the BPRS and
FCQ Positive Symptom scales. One possible expla-
nation is that lower occurrence of positive psychotic
symptoms in the ARMS group led to a distribution
of positive symptoms with a lower spread and
higher positive skew than in the FEP group which in
turn might have led to a stronger attenuation of the
correlation.
With regard to the moderating influence of
gender, we found that women showed a higher asso-
ciation between BPRS and SSP Positive Symptoms
FIGURE 2. Diagnostic Group × Self-rating scale interactions. P-values were adjusted for multiple testing by the Benjamini–Hochberg
method. ARMS, at-risk mental state; BPRS, Brief Psychiatric Rating Scale; FCQ, Frankfurt Complaint Questionnaire; FEP, first-episode
psychosis; PS, Paranoid Scale; SANS, Scale for the Assessment of Negative Symptoms; SSP, Selfscreen-Prodrome; Grey shaded
area denotes confidence interval. , ARMS; , FEP.
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than men, suggesting that women are more accu-
rate in reporting their positive psychotic symptoms.
This finding stands in contrast to the study of
Lincoln et al.4 which did not find an influence of
gender on the rating of positive psychotic symp-
toms. However, the gender effect we found should
be interpreted with caution because there was no
influence of gender in the two other comparisons
regarding positive symptoms (i.e. BPRS vs. FCQ
Positive Symptoms and BPRS vs. PS Positive Symp-
toms) and the effect was only significant when
P-values were not corrected for multiple testing.
Furthermore, our results did not support earlier
studies demonstrating that women report their
affective symptoms more accurately than men.23,24
However, these studies are difficult to compare with
our study because theywere based onmixed patient
samples.
Our study has some limitations. Firstly, even
though we had improved the comparability of the
scales by forming new subscales, we were quite
limited in the item content and thus it is possible
that our subscales still insufficiently covered the
same symptom dimensions. Other studies solved
this problem using newly constructed self-rating
questionnaires,9 modified observer-ratings to self-
questionnaires16 or concentrated their analysis on a
special symptom dimension.4 Secondly, although
we had obtained self-rating and observer-rating
from 220 patients in total, a relatively large propor-
tion of these had to be excluded because the time
difference between self-rating and observer-rating
was too large. Thirdly, we assumed according to the
literature6 that observer-ratings are closer to ‘the
truth’ and therefore represent the gold standard.
However, in order to verify this we would have to
link both types of assessment to an external cri-
terion. Future studies should directly assess the
value of both types of assessment. For example, it is
likely that observer-ratings are better for an accurate
diagnosis whereas self-ratings provide additional
information that can help increase treatment
compliance.7
Taken together, we found that the associations
between self-rating and observer-rating were rather
low. Contrary to our expectations, they were neither
FIGURE 3. Gender × Self-rating scale interactions. P-values were adjusted for multiple testing by the Benjamini–Hochberg method.
ARMS = at-risk mental state; BPRS, Brief Psychiatric Rating Scale; FCQ, Frankfurt Complaint Questionnaire; FEP, first-episode psychosis;
PS, Paranoid Scale; SANS, Scale for the Assessment of Negative Symptoms; SSP, Selfscreen-Prodrome. Grey shaded area denotes con-
fidence interval. , women; , men.
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higher in ARMS than in FEP patients, nor higher in
women than in men when corrected for multiple
testing. The results of our study therefore imply that
self-rating scales cannot be a substitute for themore
time-consuming observer-rating scales and vice
versa.
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4 Discussion 
The aim of this dissertation was on one hand to replicate findings of elevated prolactin levels 
in antipsychotic-naïve ARMS and FEP patients and to further investigate its relation to 
psychopathological symptoms and transition to psychosis. On the other hand we wanted to 
elucidate whether there are any sex differences in emerging psychosis specifically regarding 
the hormone prolactin, cognitive functioning and the correlation of self- and observer-ratings 
of psychopathology. In the following sections the results of the three publications are 
discussed.  
 
4.1 The role of prolactin in emerging psychosis 
In publication 1, the role of prolactin was investigated in 116 antipsychotic-naïve ARMS and 
49 antipsychotic-naïve FEP patients. A high percentage of antipsychotic-naïve ARMS and 
FEP patients in our sample were suffering from hyperprolactinemia. We could not show a 
difference in prolactin levels between ARMS and FEP patients. Furthermore, prolactin was 
not significantly associated with any BPRS subscale and prolactin was not a significant 
predictor of transition to psychosis.  
According to our reference standard only 2.5% of people in the normal population are 
expected to fulfil criteria for hyperprolactinemia. In contrast, in our Fepsy-study sample 32% 
of ARMS and 35% of FEP patients presented with hyperprolactinemia. Similarly high 
proportions have been reported in previous studies (Aston et al., 2010; A. Riecher-Rössler et 
al., 2013). Because hyperprolactinemia can have severe consequences including 
amenorrhea, galactorrhoea, a lack of estrogen with acceleration of osteoporosis, urogenital 
symptoms and skin aging etc. in women and a lack of libido, erectile dysfunction, dry skin, 
and osteoporosis etc. in men (Rajkumar, 2014; A. Riecher-Rössler, Schmid, Bleuer, & 
Birkhäuser, 2009) it requires clinical attention. The negative consequences of 
hyperprolactinemia are often attributed to antipsychotics and can be a reason for non-
compliant behaviour. Thus, it is important to measure prolactin levels before treatment to 
reveal a possible pre-existing hyperprolactinemia.  
Prolactin levels in ARMS and FEP patients did not significantly differ. This finding is in 
accordance with the only other study that compared prolactin levels between ARMS and FEP 
patients (Montalvo et al., 2014) and could indicate that stress levels are not higher in FEP 
than in ARMS patients. On the other hand, studies investigating the stress hormone cortisol 
have reported higher levels in FEP than in ARMS patients (Aiello et al., 2012; Holtzman et 
al., 2013; Walker et al., 2013). Similarly, we could not find associations between prolactin 
levels and BPRS subscales, whilst associations between the stress hormone cortisol and the 
severity of positive and nonspecific symptoms have been shown in the literature (Aiello et al., 
2012; Holtzman et al., 2013; Walker et al., 2013). However, the non-significant associations 
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between prolactin levels and BPRS subscales are consistent with our finding of no difference 
in prolactin levels between ARMS and FEP patients and with a study of Shrivastava and 
Tamhane (2000) who also did not find an association of prolactin levels with BPRS 
subscales.  
Even though, prolactin was not predictive of transition to psychosis, this finding is consistent 
with a study of Perkins et al. (2015) where the expression of plasma analytes reflecting 
inflammation, oxidative stress, hormones and metabolism was measured in a sample of 72 
ARMS patients and found that prolactin was not selected as a predictor of transition to 
psychosis by a machine learning algorithm. Contradictory results were found by Labad et al. 
(2015). Hence, no definite conclusion can be drawn. 
 
4.2 Sex differences in prolactin levels, cognitive functioning and its influence on correlations 
between self- and observer-rating of psychopathology  
In this section I aim at summarizing and discussing all sex specific findings from publication 
1, 2 and 3. Regarding the first publication entitled “Sex differences in prolactin levels in 
emerging psychosis: Indication for enhanced stress reactivity in women” (116 ARMS and 49 
FEP have been included) we found that prolactin was more increased in women than in men 
after correction for the normal biological variation between the sexes (ARMS + FEP). This is 
not in line with our hypothesis which was formulated on the basis of the meta-analysis of 
Gonzalez-Blanco et al. (2016) who found more pronounced differences between patients and 
controls in men than in women. Additionally, hyperprolactinemia was more frequent in 
women than in men (ARMS + FEP). One possible explanation for the discrepancies of the 
results could be that in the metaanalysis of Gonzalez-Blanco (2016) only studies with a 
healthy control sample have been included. Therefore, they disregarded an important study 
in the field, namely, the study of Riecher-Rössler and the EUFEST study group (2013), which 
found hyperprolactinemia to be present in 50% of antipsychotic-naïve female FEP patients 
but only in 36.5% of antipsychotic naïve male FEP patients. There is additional support for 
our finding of higher prolactin levels in women by a study of Lennartsson and Jonsdottir 
(2011) who demonstrated that women showed stronger prolactin responses to the Trier 
Social Stress Test (Kirschbaum, Pirke, & Hellhammer, 1993), albeit only at a trend-level. 
 
The second publication “Sex differences in cognitive functioning in at-risk mental state for 
psychosis, first episode psychosis and healthy control subjects” is the first study investigating 
sex-related neurocognitive performance differences in a sample of HC, ARMS and FEP 
patients. In total, 118 ARMS, 88 FEP and 86 HC completed a cognitive test battery covering 
the domains of executive functions, attention, working memory, verbal learning and memory, 
IQ and speed of processing (see also publication 2 for more details). Due to the fact that sex-
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related cognitive performance differences have been found to be rather small (Hyde, 1981), 
we decided to discuss findings that were significant at an uncorrected level to account for 
potential false negative results. 
Our main finding that women perform better in the domain of verbal learning and memory 
across all diagnostic groups (HC, ARMS, FEP) is in line with our hypothesis and consistent 
with a large body of evidence (Bozikas et al., 2010; Halari et al., 2005; Jimenez, Mancini-
Marie, Lakis, Rinaldi, & Mendrek, 2010; Longenecker et al., 2010; Walder et al., 2006). The 
results suggest that the sex advantage of women in verbal learning and memory is equally 
present in ARMS as in FEP and HC individuals, as we did not find an interaction effect 
between diagnostic group (HC, ARMS, FEP) and sex (men, women) (Nieuwenhuis, 
Forstmann, & Wagenmakers, 2011). Additionally, we found that men had a shorter reaction 
time in the 2-back task than women independent of diagnostic group. Probably, this could 
indicate that men have a superior working memory performance since they responded faster 
during the target trials, while maintaining a comparable performance level. As no sex 
differences in reaction time during Continuous Performance Test (CPT-OX; Rosvold, Mirsky, 
Sarason, Bransome, & Beck, 1956) and Go/No-Go (subtest of the Test of Attentional 
Performance [TAP]; Zimmermann & Fimm, 1993) were detected, the result above cannot be 
better explained by a generally enhanced processing speed. Additionally, we found a 
significant sex × group interaction effect in verbal IQ (better performance of women in HC 
and worse performance in ARMS and FEP) which is difficult to explain as it is not 
substantiated by the literature. A potential explanation for a worse performance of women in 
the ARMS and FEP group could be that women in our sample do present more severe 
positive symptoms than men as indicated by the BPRS psychosis/thought disturbance 
dimension score described by Velligan et al. (2005). We have included fewer women than 
men in the Fepsy-study because we reached probably only the really severe ill female 
patients which could be the reason for more positive psychotic symptoms in women. 
In the third publication, correlations between self-rating and observer-rating of 
psychopathology in ARMS and FEP patients and the influence of disease stage and sex on 
these correlations have been investigated in a sample of 126 ARMS and 94 FEP patients. 
The BPRS (Lukoff et al., 1986) and the Scale for the Assessment of Negative Symptoms 
(SANS; Andreasen, 1989) were used as observer-ratings and the Frankfurt Complaint 
Questionnaire (FCQ; Süllwold, 1986), the Selfscreen-Prodrome (SSP; Kammermann, 
Stieglitz, & Riecher-Rossler, 2009) and the Paranoid Scale (PS; Zerssen & Koeller, 1976) 
were used as self-ratings of psychopathological symptoms (see also publication 3 for more 
details). As the second important point of my thesis is sex differences in emerging psychosis, 
I will mainly discuss the aspect of the moderating factor sex in relation to the agreement 
between self- and observer-ratings and just shortly describe the other findings (see also 
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publication 3). In accordance with the second publication, we decided to discuss findings that 
were significant at an uncorrected level to account for potential false negative results. 
Generally, the agreements between self-rating and observer-rating were rather low. Two 
significant correlations (out of seven) between self- and observer-rating covering the same 
symptom dimension (one with positive and one with negative symptoms) have been found. 
This finding stands in contrast to earlier studies which pointed out that negative symptoms 
are more difficult to report accurately than positive symptoms (Hamera et al., 1996; Preston 
& Harrison, 2003). Furthermore, also the lack of association between scales measuring 
affective symptoms is in contrast to previous studies (Biancosino et al., 2007; Hartmann et 
al., 2013).  
With regard to the moderating influence of disease stage, we could not confirm that the 
agreement between self- and observer-rating is higher in AMRS than in FEP patients. When 
taking sex as influencing factor into account it has been found that women showed a higher 
association between BPRS and SSP positive symptoms than men, suggesting that women 
more accurately report their positive psychotic symptoms. This finding has to be interpreted 
with caution because there was no influence of sex in the two other comparisons regarding 
positive symptoms (i.e. BPRS vs. FCQ positive symptoms and BPRS vs. PS positive 
symptoms) and it is in contrast to the finding of Lincoln et al. (2010). Furthermore, findings of 
earlier studies demonstrating that women report their affective symptoms more accurately 
than men (Jolly et al., 1994; Shain et al., 1990) are not supported by our study. However, it 
should be noted that these earlier studies are difficult to compare as they were based on 
mixed patient samples. 
5 Conclusion and Perspectives  
Taken together, the results of my first publication provide further evidence for frequent 
hyperprolactinemia in emerging psychosis and highlight that this can be observed in 
antipsychotic-naïve patients (ARMS, FEP). Moreover, women in our patient sample (ARMS, 
FEP) had higher prolactin levels even after correction for the normal biological variation 
between sexes. The question whether elevated prolactin levels are specific for emerging 
psychosis or rather associated with emerging illness (e.g. depression etc.) in general could 
not be ruled out. Hence, for future studies, recruitment of control groups (e.g. depressive 
controls but also healthy controls) should be planned. Furthermore, future studies should 
also assess individual perceived stress levels using, for example, the perceived stress scale 
(PSS; Cohen, Kamarck, & Mermelstein, 1983). Myin-Germeys et al. (2004) showed already 
earlier that women are more characterized by increased stress sensitivity compared with 
men. The hypothesis of increased stress sensitivity suggests that not the stress level itself is 
responsible for developing symptoms but rather the way subjects react to it (Myin-Germeys 
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et al., 2004). Thus, it would be very interesting to investigate if prolactin levels may be an 
indicator for the increased stress sensitivity in women (correlation between PSS and 
prolactin), which would help to further clarify the role of prolactin in emerging psychosis.  
The results of the second study suggest that sex differences in cognitive functioning in 
ARMS and FEP patients are not different from those seen in HC. Specifically, the female 
advantage in verbal learning and memory, which has frequently been found in HC seems to 
be equally present in ARMS and FEP patients. Nevertheless, the effects were small probably 
also because our neuropsychological tasks were originally selected to assess the risk for 
psychosis and not specifically to detect sex differences. Our test battery did not include some 
of the most sensitive tasks to detect sex differences such as visuo-spatial or mental rotation 
tasks. Beside this, future studies should also consider menstrual status in women as 
neuropsychological performance of women has been shown to fluctuate with their monthly 
cycle (Farage, Osborn, & MacLean, 2008; Hausmann, Slabbekoorn, Van Goozen, Cohen-
Kettenis, & Gunturkun, 2000; Hoff et al., 2001; Kimura & Hampson, 1994) 
Altogether, the third study reveals that the agreements between self-rating and observer-
rating of psychopathology were rather low and generally not higher in women than in men. 
This implies that self-rating-scales cannot be a substitute for the more time-consuming 
observer-rating scales and vice versa neither in men nor in women.  
Overall, the current dissertation reveals few sex differences in the second and third 
publication. The sex differences in cognitive functioning (publication 2) resemble those of the 
general population and were not different between HC and patients (ARMS+FEP). On the 
other hand, the sex difference regarding prolactin (more frequent hyperprolactinemia in 
women and higher prolactin levels in women as compared to men) seems to be more 
pronounced and represents a good point to continue and deepen research concerning sex 
dependent stress reactivity in emerging psychosis and the underlying biological parameters. 
Furthermore, our results imply that hyperprolactinemia is not only caused by antipsychotics 
but prolactin levels can be affected independent of any medication. Therefore, prolactin 
should be measured already before any antipsychotic treatment to exclude a pre-existing 
hyperprolactinemia, which would need thorough investigation. 
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